

Publications of Department of Medicine in 2023

A. Refereed Papers Included in Science Citation Index:

- ¹: 表此篇文章以榮總之名義發表。
- ²: 表此篇文章以榮總及陽明之名義發表。
- ³: 表此篇文章為國外進修時之著作。
- ⁴: 表此篇文章之第一作者為本部其它科之醫師。
- ⁵: 表此篇文章之第一作者為本院其它部科或他院之醫師。
- *: 為通訊作者
- #: Equal contribution

Gastroenterology

1. ^{2,5}Bekaii-Saab T*, Okusaka T, Goldstein D, Oh DY, Ueno M, Ioka T, Fang WJ, Anderson EC, Noel MS, Reni M, Choi HJ, Goldberg JS, Oh SC, Li CP, Tabernero J, Li J, Foos E, Oh C, Van Cutsem E. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial. *EClinicalMedicine* 2023;58:101897. (IF:15.1)
2. ^{2,5}Chang TS, Huang CF, Kuo HT, Lo CC, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Chen CY, Tseng KC, Hung CH*, Yu ML*. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naive patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry. *Hepatology* 2023;17(3):550-561. (IF:6.6)
3. ^{1,5}Chen MJ, Chen PY, Fang YJ, Bair MJ, Chen CC, Chen CC, Yang TH, Lee JY, Yu CC, Kuo CC, Chiu MC, Chou CK, Chen CY, Hu WH, Tsai MH, Hsu YC, Shun CT, Luo JC, Lin JT, El-Omar EM, Wu MS, Liou JM*. Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line *Helicobacter pylori* eradication: two multicentre, open-label, randomised controlled, non-inferiority trials. *Lancet Gastroenterol Hepatol* 2023;8(7):623-634. (IF:35.7)
4. ^{2,5}Chen TH, Chen MH, Hung YP, Chiang NJ, Huang KH, Lin YH, Lin RW, Chao Y, Li AFY, Yu HY, Hwang HE, Yeh YC, Wang YC*, Fang WL*. Elevated PD-L1 Expression and Microsatellite Instability in Elderly Patients With Gastric Cancer. *J Immunother* 2023;46(3):111-119. (IF:3.9)
5. ^{2,5}Chen Y, Tseng SH, Chen CY*, Tsai YH*. Application of Intestinal Barrier Molecules in the Diagnosis of Acute Cellular Rejection After Intestinal Transplantation. *Transpl Int* 2023;36:11595. (IF:3.1)
6. ²Chen YJ, Hou MC*, Yang TC, Lee PC, Huang YH, Lee FY. Triage policy to postpone endoscopy for patients with low-risk varices is safe during the lockdown period of COVID-19 pandemic. *BMC Gastroenterol* 2023;23(1):236. (IF:2.4)
7. ²Chen YJ, Hou MC*, Yang TC, Lee PC, Wang YP, Huang YH, Lee FY. Effectiveness of

- betadine-coating gastrostomy tube to reduce peristomal infection after percutaneous endoscopic gastrostomy: a randomized controlled trial. *BMC Gastroenterol* 2023;23(1):155. (IF:2.4)
8. ^{2,5}Chiorean EG*, Picozzi V, Li CP, Peeters M, Maurel J, Singh J, Golan T, Blanc JF, Chapman SC, Hussain AM, Johnston EL, Hochster HS. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial. *Cancer Med* 2023;12:20353-20364. (IF:4)
 9. ^{2,5}Chiu HC, Liu CA*, Tseng HS, Ling K, Tsai YC, Huang HE, Wu PS, Lee RC. Predictors of technical success of percutaneous transhepatic common bile duct stone removal: is it only a matter of stone size?. *Eur Radiol* 2023;33(10):6872-6882. (IF:5.9)
 10. ^{2,5}Chiu YF, Liu TW, Shan YS, Chen JS, Li CP, Ho CL, Hsieh RK, Hwang TL, Chen LT, Chang HJ*. Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which Patients Are Suited for Additional Adjuvant Chemoradiation Therapy: From a Prospective Randomized Study. *Int J Radiat Oncol Biol Phys* 2023;117(1):74-86. (IF:7)
 11. ^{2,5}Choi WM, Yip TCF, Wong GLH, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Cant H, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin W, Yang YH, Lim YS*. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. *J Hepatol* 2023;78(3):534-542. (IF:25.7)
 12. ^{2,4}Chuang C, Lee KC, Wang YP, Lee PC, Chang TE, Huang YH, Lin YT*, Hou MC*. High carriage rate of extended-spectrum β -lactamase *Enterobacterales* and diarrheagenic *Escherichia coli* in healthy donor screening for fecal microbiota transplantation. *Eur J Clin Microbiol Infect Dis* 2023;42(9):1103-1113. (IF:4.5)
 13. ^{2,5}Dharmapuri S*, Ozbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D'Alessio A, Rimassa L, Pinato DJ, Ang C. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma. *World J Gastrointest Oncol* 2023;15(11): 1900-1912. (IF:3.0)
 14. ²Fu CC, Chen YJ*, Su CW, Wei CY, Chu CJ, Lee PC, Huo TI, Huang YH, Huang HC, Wu JC, Hou MC. The outcomes and prognostic factors of patients with hepatocellular carcinoma and Child-Turcotte-Pugh class B. *J Chin Med Assoc* 2023;86(10):876-884. (IF:3)
 15. ²Fu CC, Wei CY, Chu CJ, Lee PC, Huo TI, Huang YH, Chao Y, Hou MC, Wu JC, Su CW*. The outcomes and prognostic factors of patients with hepatocellular carcinoma and normal serum alpha fetoprotein levels. *J Formos Med Assoc* 2023;122(7):593-602. (IF:3.2)
 16. ^{2,5}Ho SY, Liu PH, Hsu CY, Huang YH, Lei HJ, Liao JI, Su CW, Hou MC, Huo TI*. Surgical resection versus transarterial chemoembolization for patients with hepatocellular carcinoma beyond Milan criteria: prognostic role of tumor burden score. *Sci Rep* 2023;13(1):13871. (IF:4.6)
 17. ^{2,5}Ho SY, Liu PH, Hsu CY, Huang YH, Liao J, Su CW, Hou MC, Huo TI*. Comparison of Four Albumin-Based Liver Reserve Models (ALBI/EZ-ALBI/PALBI/PAL) against MELD for

Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. *Cancers* 2023;15(7):1925. (IF:5.2)

18. ^{2,5}Ho SY, Yuan MH, Liu PH, Hsu CY, Huang YH, Liao J, Su CW, Wang CL, Hou MC, Huo TL*. Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. *Scand J Gastroenterol* 2023;58(1):61-69. (IF:1.8)
19. ²Hsieh YC, Joo SK, Koo BK, Lin HC, Lee DH, Chang MS, Park JH, So YH, Kim W*. Myosteatorsis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression. *Clin Gastroenterol Hepatol* 2023;21(2):388-397. (IF:12.6)
20. ^{2,5}Huang CJ, Hsu SJ, Hsu YC, Chen LK, Li C, Huang HC*, Lee YH*. Synthesis, characterization, and biological verification of asialoglycoprotein receptor-targeted lipopolysaccharide-encapsulated PLGA nanoparticles for the establishment of a liver fibrosis animal model. *Biomater Sci* 2023;11(19):6650-6662. (IF:6.6)
21. ²Hung YW, Lee IC, Chi CT, Lee RC, Liu CA, Chiu NC, Hwang HE, Chao Y, Hou MC, Huang YH*. Radiologic Patterns Determine the Outcomes of Initial and Subsequent Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma. *Liver Cancer* 2023;May 15 :DOI: 10.1159/000530950. (IF:13.8)
22. ^{2,5}Huo TI*, Ho SY, Liao J. Look for new biomarkers in the management of hepatocellular carcinoma: What the hepatologists may need to know. *Liver Int* 2023;43(1):260-261. (IF:6.7)
23. ^{2,5}Huo TI*, Ho SY, Liao JI. A commentary on 'development and validation of safety and efficacy-associated risk calculator for hepatocellular carcinoma in the elderly after resection (searcher): a multi-institutional observational study'. *Int J Surg* 2023;109(2):204-205. (IF:15.3)
24. ^{2,5}Huo TI*, Ho SY, Liao JI. A commentary on 'Nomograms for predicting the recurrence probability and recurrence-free survival in patients with hepatocellular carcinoma after conversion hepatectomy based on hepatic arterial infusion chemotherapy: a multicenter, retrospective study' (*Int J Surg* 2023; 109:1299-310). *Int J Surg* 2023;109(8):2529-2530. (IF:15.3)
25. ^{2,5}Huo TI*, Ho SY, Liao JI. Predicting post-resection early recurrence of hepatocellular carcinoma: Defining the role of microvascular invasion. *Liver Int* 2023;43:2826-2827. (IF:6.7)
26. ^{2,5}Huo TI*, Liao JI, Ho SY. Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITy, mALF and beyond. *Hepatol Int* 2023;17(2):512-513. (IF:6.6)
27. ^{2,5}Joerg V, Scheiner B, D'Alessio A, Fulgenzi CAM, Schonlein M, Kocheise L, Lohse AW, Huber S, Wege H, Kaseb A, Wang YH, Mathew A, Kuang A, Muzaffar M, Abugabal YI, Chamseddine S, Phien S, Cheon J, Lee PC, Balcar L, Krall A, Ang C, Wu L, Saeed A, Huang YH, Bengsch B, Rimassa L, Weinmann A, Stauber R, Korolewicz J, Pinter M, Singal AG, Chon HJ, Pinato DJ*, Schulze K, von Felden J*. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study. *Hepatol Commun* 2023;7(11):e0302. (IF:5.1)
28. ^{2,5}Kao WY, Tan ECH*, Lee HL, Huang YH, Huo TI, Chang CC, Chiou JF, Hou MC, Wu JC, Su CW*. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy. *Aliment Pharmacol Ther* 2023;57:1299-1312. (IF:7.6)
29. ^{2,5}Kee KM, Chen CH, Hu JT, Huang YH, Wang TE, Chau GY, Chen KH, Chen YL, Lin CC,

4 / SCI papers

- Hung CF, Huang SF, Liu TW, Ku HY, Huang BS, Wang YP, Tseng HP, Chiang CJ, Lu SN*. Secular Trends of Clinical Characteristics and Survival of Hepatocellular Carcinoma in Taiwan from 2011 to 2019. *Viruses-Basel* 2023;15(1):126. (IF:4.7)
30. ^{2,5}Kim JS, Chen MH, Wang HE, Lu CL, Wang YP*, Zhang B*. Inflammatory Bowel Disease and Neurodegenerative Diseases. *Gut Liver* 2023;17:495-504. (IF:3.4)
31. Lai JI*, Kuo TH, Huang KJ, Chai LMX, Lee MH, Liu CY, Tsai YF, Huang CC, Tseng LM, Hsu CC*, Chao TC. Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients. *Oncologist* 2023;23-Nov:oyad304. (IF:5.8)
32. ²Lee KC*, Wu PS, Lin HC*. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. *Clin Mol Hepatol* 2023;29(1):77-98. (IF:8.9)
33. ^{2,5}Lee MH*, Wu PF, Chen TI, Chan C, Lin HH, Huang YH, Chen HY, Lin YT, Chen CJ. Tenofovir use is associated with a decreased risk of hepatocellular carcinoma among men with HIV irrespective of coinfection status. *JHEP Rep* 2023;5(3):100634. (IF:8.3)
34. ²Lee PC, Lee KC, Yang TC, Lu HS, Cheng TY, Chen YJ, Chiou JJ, Huang CW, Yang UC, Tan ECH, Chou SH, Kuo YL, Schnabl B, Huang YH, Hou MC*. Sarcopenia-related gut microbial changes are associated with the risk of complications in people with cirrhosis. *JHEP Rep* 2023;5(1):100619. (IF:8.3)
35. ^{2,5}Leow YW, Chan WK*, Goh GBB, Wong VWS, Fan JG, Kim YS, Kim SU, Nakajima A, Seto WK, Lee IC, Huang YH, Kim YJ, Young JJ, Chow WC. Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP-Asia study. *J Viral Hepatitis* 2023;30(4):319-326. (IF:2.5)
36. ²Li CJ, Chang TE, Hou MC*, Huang YH, Lee PC, Chang NW, Chen YJ, Lee FY. Lockdown period during SARS COVID-19 endemic outbreak in Taiwan did not cause an increase of the complications nor mortality of patients received endoscopic retrograde cholangiopancreatography: A single-center retrospective study. *J Chin Med Assoc* 2023;86(2):147-154. (IF:3)
37. ^{2,5}Liang YJ, Chiou YW, Chiu APT, Shiao MS, Teng W, Lin CW, Cheng ML, Huang YH, Liang KH, Su CW, Lai CY, Chen CL, Wu JC*. Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR-122. *J Med Virol* 2023;95(12):- . (IF:12.7)
38. ²Liao JI, Ho SY*, Liu PH, Hsu CY, Huang YH, Su CW, Hou MC, Huo TI*. Prognostic Prediction for Patients with Hepatocellular Carcinoma and Ascites: Role of Albumin-Bilirubin (ALBI) Grade and Easy (EZ)-ALBI Grade. *Cancers* 2023;15(3):753. (IF:5.2)
39. ^{2,5}Liao TL*, Chen YM, Tang KT, Yang YY, Chen DY, Chan TH, Tsai HJ, Hsieh SL*. CLEC18A Impairs Phagocytosis by Reducing FcγRIIA Expression and Arresting Autophagosome-Lysosome Fusion. *Microbiol Spectr* 2023;11(3):e0290322. (IF:3.7)
40. ^{2,5}Liao YL, Wang TJ*, Su CW, Liang SY, Liu CY, Fan JY. Efficacy of a Decision Support Intervention on Decisional Conflict Related to Hepatocellular Cancer Treatment: A Randomized Controlled Trial. *Clin Nurs Res* 2023;32(1):233-243. (IF:1.7)
41. ^{2,5}Lim M, Muquith M, Miramontes B, Lee CJ, Espinoza M, Huang YH, Hsiehchen D*. Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma. *Hepatology* 2023;78:1755-1762. (IF:14)

42. ¹Liou JM, Jiang XT, Chen CC, Luo JC, Fang YJ, Bair MJ, Chen MJ, Chen CC, Lee JY, Yang TH, Chen PY, Chen CY, Chou CK, Shun CT, Hsu WF, Tseng CH, Hsu YC, Chang CY, Lin JT, El-Omar EM*, Wu MS*, for the Taiwan Gastrointestinal Disease and Helicobacter Consortium. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for *Helicobacter pylori* eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial. *Lancet Gastroenterol Hepatol* 2023;8(3):228-241. (IF: 45.042)
43. ^{2,5}Liu CH, Lin HC, Kao JH*. Toward the hepatitis C virus elimination in Asia: The policy forum from the 2023 Asian Pacific Association of the Study of the Liver (APASL). *J Formos Med Assoc* 2023;122(12):1234-1237. (IF:3.2)
44. ²Luan CH, Su PS, Chu CJ*, Lin CC, Su CW, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC. Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response. *J Chin Med Assoc* 2023;86(9):795-805. (IF:3)
45. ²Pan YL, Wu PS*, Chen JH, Chen LY, Fang WL, Chau GY, Lee KC*, Hou MC. Early cholecystectomy following percutaneous transhepatic gallbladder drainage is effective for moderate to severe acute cholecystitis in the octogenarians. *Arch Gerontol Geriatr* 2023;106:104881. (IF:4)
46. ²Pun CK, Chang CC, Chuang CL, Huang HC*, Hsu SJ*, Huang YH, Hou MC, Lee FY. Dual angiotensin receptor and neprilysin inhibitor reduced portal pressure through peripheral vasodilatation and decreasing systemic arterial pressure in cirrhotic rats. *J Chin Med Assoc* 2023;86(9):786-794. (IF:3)
47. ^{2,5}Su YY, Chiang NJ, Yang YH, Yen CJ, Bai LY, Chiu CF, Chuang SC, Yang SH, Chou WC, Chen JS, Chiu TJ, Chen YY, Chan DC, Peng CM, Chiu SC, Li CP*, Shan YS*, Chen LT. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. *Cancers* 2023;15(4):1008. (IF:5.2)
48. ^{2,5}Talbot T, D'Alessio A, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Muzaffar M, Fulgenzi CAM, Amara S, Naqash AR, Gampa A, Pillai A, Wang YH, Khan U, Lee PC, Huang YH, Bengsch B, Bettinger D, Mohamed Y, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Kudo M, Weinmann A, Galle PR, Muhammed A, Cortellini A, Vogel A, Pinato DJ*. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study. *Liver Int* 2023;43(3):695-707. (IF:6.7)
49. ^{2,5}Tempero MA*, Pelzer U, O'Reilly EM, Winter J, Oh D, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassinetti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Taberero J, Li MY, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M. Adjuvant *nab*-Paclitaxel plus Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. *J Clin Oncol* 2023;41(11):2007-2019. (IF:45.4)
50. ^{2,5}Tsai HJ, Wu MJ, Chen CH, Yang SS, Huang YH, Chang YZ, Chang HR*, Lee TY*. Risk Stratification for Hepatitis B Virus Reactivation in Kidney Transplant Recipients With Resolved HBV Infection. *Transpl Int* 2023;36:11122. (IF:3.1)
51. ^{2,5}Tsai PC, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH,

- Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Hsieh MH, Huang JF, Dai CY, Chung WL, Chen CY*, Yu ML*. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. *J Hepatol* 2023;78(2):281-292. (IF:25.7)
52. ^{2,5}Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schonlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Zanuso V, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ, Sharma R*. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma. *Hepatol Int* 2023;17(4):904-914. (IF:6.6)
53. ^{2,4}Wang YP, Zhang B*, Wang HE, Bai YM, Tsai SJ, Chen TJ, Chen MH*. Risk of Attempted Suicide Among Patients With IBD: A Nationwide Longitudinal Follow-up Study. *Dis Colon Rectum* 2023;66(9):E938-E945. (IF:4.1)
54. ^{2,5}Wu CH, Lai CL, Teng CLJ, Fang WL, Huang KH, Li AFY, Yu HY, Chiang NJ, Chao Y, Hung YP*, Chen MH*. Immunoprofile of adenosquamous carcinoma in gastric cancer. *J Chin Med Assoc* 2023;86(6):542-548. (IF:3)
55. ^{2,5}Wu YL, van Hyfte G, Ozbek U, Reincke M, Gampa A, Mohamed YI, Nishida N, Wietharn B, Amara S, Lee PC, Scheiner B, Balcar L, Pinter M, Vogel A, Weinmann A, Saeed A, Pillai A, Rimassa L, Naqash AR, Muzaffar M, Huang YH, Kaseb AO, Kudo M, Pinato DJ, Ang C*. Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. *Front Oncol* 2023;13:1128569. (IF:4.7)
56. ²Yang TC, Chen WC, Hou MC*, Chen PH, Lee PC, Chang CY, Lu HS, Chen YJ, Hsu SJ, Huang HC, Luo JC, Huang YH, Lee FY. Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial. *Gut* 2023;14-Dec:gutjnl-2023-330419. (IF:24.5)
57. ^{2,5}Yen FS, Hou MC, Liu JS, Hsu CC*, Hwu CM*. Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes. *Front Med* 2023;9:962337. (IF:3.9)
58. ^{2,5}Yen FS, Hou MC, Pan CW, Liu JS, Hsu CC*, Hwu CM*. The Risk of Severe Hypoglycemia and Mortality in Patients With Type 2 Diabetes and Discharged With Acute Liver Injury. *Diabetes Care* 2023;46(1):20-27. (IF:16.2)
59. ^{2,5}Yu ML, Wang CY, Lee MH, Ou HY, Cheng PN, Tu ST, Huang JF, Chen JF, Hu TH, Hsu CC, Kao JH, Chen CJ, Lin HC*, Huang CN*. TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes. *J Formos Med Assoc* 2023;122(3):202-220. (IF:3.2)

Cardiology

1. ^{2,5}Bautista JAL, Lin CY*, Lu CT, Lo LW, Lin YJ, Chang SL, Hu YF, Chung FP, Tuan TC, Chao TF, Liao JN, Chang TY, Kuo L, Liu CM, Liu SH, Wu C, Kuo MJ, Li GY, Huang YS, Wu SJ, Siow YK, Son NND, Tran DC, Chen SA. Clinical significance of substrate

- characteristics and ablation outcomes in patients with atrial fibrillation and significant functional mitral regurgitation. *Front Cardiovasc Med* 2023;10:1265890. (IF:3.6)
2. ^{2,5}Bucci T, Shantsila A, Romiti GF, Teo WS, Park HW, Shimizu W, Mei DA, Tse HF, Proietti M, Chao TF*, Lip GYH*. Sex-related differences in presentation, treatment, and outcomes of Asian patients with atrial fibrillation: a report from the prospective APHRS-AF Registry. *Sci Rep* 2023;13(1):18375. (IF:4.6)
 3. ^{2,5}Chan CS, Lin FJ, Chen YC, Lin YK, Higa S, Chen SA, Chen YJ*. Glucagon-like Peptide-1 Receptor Activation Reduces Pulmonary Vein Arrhythmogenesis and Regulates Calcium Homeostasis. *Int J Mol Sci* 2023;24(17):13100. (IF:5.6)
 4. ^{2,5}Chan YH, Chan CY, Chen SW, Chao TF*, Lip GYH. Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies. *Europace* 2023;25(10):euad288. (IF:6.1)
 5. ^{2,5}Chan YH*, Chao TF, Chen SW, Kao YW, Huang CY, Chu PH. The Association of Background Medications on Initial eGFR Change and Kidney Outcomes in Diabetic Patients Receiving SGLT2 Inhibitor. *Clin J Am Soc Nephrol* 2023;18(7):858-868. (IF:9.8)
 6. ^{2,5}Chan YH*, Chao TF, Chen SW, Kao YW, Huang CY, Chu PH*. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor. *Eur Heart J-Qual Care Clin Outcomes* 2023;9(4):397-407. (IF:5.2)
 7. ^{2,5}Chang HC, Cheng HM, Kuo L, Lee DY, Sung SH, Chen CH, Yu WC*. Risk stratification in patients with hypertrophic cardiomyopathy: Looking beyond the left side myocardial function. *J Chin Med Assoc* 2023;86(1):19-25. (IF:3)
 8. ^{2,5}Chang HC, Kuo L, Sung SH, Weng CY, Chen CK, Niu DM, Chen SA, Yu WC*. Left Ventricular Apical Aneurysm in Fabry Disease: Implications for Clinical Significance and Risk Stratification. *J Am Heart Assoc* 2023;12(1):e027041. (IF:5.4)
 9. ^{2,5}Chang LH, Chu CH, Huang CC, Lin LY*. Soluble tumor necrosis factor receptor type 1 predicts cardiorenal outcomes and better associated with distinct cardiovascular or renal outcomes than precedential renal or cardiovascular events in type 2 diabetes mellitus. *Ther Adv Endocrinol Metab* 2023;14:20420188231207345. (IF:3.8)
 10. ^{2,5}Chang TT*, Li SY, Lin LY, Chen C, Chen JW*. Macrophage inflammatory protein-1 β as a novel therapeutic target for renal protection in diabetic kidney disease. *Biomed Pharmacother* 2023;161:114450. (IF:7.5)
 11. ²Chang TY, Chao TF*, Lin CY, Lin YJ, Chang SL, Lo LW, Hu YF, Chung FP, Chen SA. Catheter ablation of atrial fibrillation in heart failure with impaired systolic function: An updated meta-analysis of randomized controlled trials. *J Chin Med Assoc* 2023;86(1):11-18. (IF:3)
 12. ²Chao TF, Unverdorben M, Kirchhof P, Koretsune Y, Yamashita T, Crozier RA, Pecun L, Chen CTY, Borrow AP, De Caterina R*. Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program. *J Clin Med* 2023;12(5):1870. (IF:3.9)
 13. ²Chao TF*, Liu CM, Liao JN. The importance of time in therapeutic range of warfarin for stroke prevention in atrial fibrillation. *Kardiol Pol* 2023;81(2):105-106. (IF:3.3)

14. ²Chao TF*, Yeh YH, Chan YH, Lin FJ, Chen TH, Pan KL, Lin JC, Lin YJ, Chen SA. The Report of Community-Based and Government-Endorsed Screening Program of Atrial Fibrillation in Taiwan. *Thromb Haemost* 2023;11-Aug:doi: 10.1055/a-2127-0690. (IF:6.7)
15. ^{2,5}Chao TH*, Yeh HI, Shyu KG, Lai CH, Lee JK, Huang CC, Wang JH, Hsieh IC, Tsai CT, Lee WL, Liu PY, Wang TD, Chen WJ, Hou CJY, T FORMOSA investigators. Rationale and Study Design of the TSOC-Fully Organized Registry for the Management of Symptomatic ACS Study (T-FORMOSA Study). *Acta Cardiol Sin* 2023;39(4):561-571. (IF:1.9)
16. ^{2,5}Chen C, Chang CC, Lee IT, Huang CY, Lin FY, Lin SJ, Chen JW, Chang TT*. High-density lipoprotein protects vascular endothelial cells from indoxyl sulfate insults through its antioxidant ability. *Cell Cycle* 2023; Dec 21:doi: 10.1080/15384101.2023.2296184. (IF:4.3)
17. ²Chen CY, Leu HB, Wang SC, Tsai SH, Chou RH, Lu YW, Tsai YL, Kuo CS, Huang PH*, Chen JW, Lin SJ*. Inhibition of Trimethylamine N-Oxide Attenuates Neointimal Formation Through Reduction of Inflammasome and Oxidative Stress in a Mouse Model of Carotid Artery Ligation. *Antioxid Redox Signal* 2023;38(1-3):215-233. (IF:6.6)
18. ^{1,5}Chen GX, Barajas-Martinez H, Ciconte G, Wu CI, Monasky MM, Xia H, Li B, Capra JA, Guo K, Zhang ZH, Chen X, Yang B, Jiang H, Tse G, Mak CM, Aizawa Y, Gollob MH, Antzelevitch C, Wilde AAM, Pappone C, Hu D*. Clinical characteristics and electrophysiologic properties of SCN5A variants in fever-induced Brugada syndrome. *EBioMedicine* 2023;87:104388. (IF:11.1)
19. ^{2,5}Chen HC, Tsai YH, Huang CC*. Triglyceride glucose index and renal function decline in Han Chinese hypertensive patients. *J Clin Hypertens* 2023;25(10):951-956. (IF:2.8)
20. ^{2,5}Chen WT, Chung FP*, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chao TF, Liao JN, Lin CY, Chang TY, Kuo L, Wu C, Liu CM, Liu SH, Hsieh YC, Li CH, Chen SA. Lower contact force predicts right pulmonary vein carina breakthrough after ablation index-guided pulmonary vein isolation using high-power short-duration. *J Cardiovasc Electrophysiol* 2023;35:60-68. (IF:2.7)
21. ²Chen WT, Li CH, Chou YH, Lin WL, Lin YJ, Chang SL, Hu YF, Chung FP, Liao JN, Tuan TC, Chao TF, Lin CY, Chang TY, Kuo L, Liu CM, Liu SH, Cheng WH, An TN, Elimam AMM, Chheng C, Nguyen TCK, Ahliah I, Kuo MR, Kao PH, Chen SA*, Lo LW*. Post-ablation augmentation of skin sympathetic nerve activity predicts a poor outcome of idiopathic ventricular arrhythmias. *J Cardiol* 2023;81(5):434-440. (IF:2.5)
22. ²Chen WT, Tsai WC, Chung FP*. A Damaged Hydrophilic Coating Can Result in Thrombus Formation on the Coronary Sinus Catheter. *Acta Cardiol Sin* 2023;39(1):198-200. (IF:1.9)
23. ²Chen YH*, Chang HH, Leu HB. Redo-transcatheter aortic valve implantation in a patient at high risk of coronary obstruction due to sinus sequestration. *Eur Heart J* 2023;44(21):1959-1959. (IF:39.3)
24. ²Chen YH*, Chang HH, Leu HB. Can it Be Verified That Membranous Septum Length Does Not Impact New Permanent Pacemaker Implantation?. *JACC-Cardiovasc Interv* 2023;16(10):1305-1305. (IF:11.3)
25. ^{2,5}Chen YY, Chung FP, Lin YJ, Chien KL*, Chang WT*. Exploring the Risk Factors of Sudden Cardiac Death Using an Electrocardiography and Medical Ultrasonography for the General Population Without a History of Coronary Artery Disease or Left Ventricular Ejection Fraction <35% and Aged >35 Years. *Circ J* 2023;87(1):139-149. (IF:3.3)

26. ^{2,5}Chen YY, Chung FP, Lin YJ, Su TC, Chang WT*, Chien KL*. Epidemiological Characteristics and Meteorological Factors of Sudden Death among General Population of Ethnic Chinese in Taiwan: An Eighteen-Year Follow-Up Report in a Community. *Acta Cardiol Sin* 2023;39(1):151-161. (IF:1.9)
27. ^{2,5}Chen YY, Lin YJ*, Hsieh YC, Chien KL, Lin CH, Chung FP, Chen SA. Atrial fibrillation as a contributor to the mortality in patients with dementia: A nationwide cohort study. *Front Cardiovasc Med* 2023;10:1082795. (IF:3.6)
28. ^{2,5}Cheng WH, Liao YC, Chen SA*. Midline ablation beyond pulmonary vein isolation? "The MiLine study". *Heart Rhythm* 2023;20(5):666-667. (IF:5.5)
29. ^{2,5}Cheng YY, Hu YF, Hsieh PCH*. The Role of Large Animal Models in Cardiac Regeneration Research Using Human Pluripotent Stem Cell-Derived Cardiomyocytes. *Curr Cardiol Rep* 2023;25:325-331. (IF:3.7)
30. ^{2,5}Cheong KI, Leu HB, Wu CC, Yin WH, Wang JH, Lin TH, Tseng WK, Chang KC, Chu SH, Yeh HI, Chen JW*, Wu YW*. The clinical significance of osteopontin on the cardiovascular outcomes in patients with stable coronary artery disease. *J Formos Med Assoc* 2023;122(4):328-337. (IF:3.2)
31. ^{2,5}Chi CC, Wu YW, Chao TH, Chen CC, Chen YJ, Cheng HM, Chiu HY, Chiu YW, Chung WH, Hsieh TY, Huang PH, Huang YH, Lin SH, Lin TH, Ueng KC, Wang CC, Wang YC, Wu NL, Hou CJY*, Tsai TF*. 2022 Taiwanese Dermatological Association (TDA), Taiwanese Association for Psoriasis and Skin Immunology (TAPSI), and Taiwan Society of cardiology (TSOC) joint consensus recommendations for the management of psoriatic disease with attention to cardiovascular comorbidities. *J Formos Med Assoc* 2023;122(6):442-457. (IF:3.2)
32. ^{2,5}Chiang CE*, Hung CL, Wu YW, Lin TH, Ueng KC, Sung SH, Wu CK, Chao TH, Lin HJ, Lin YH, Huang JL, Chen MYC, Lin PL, Chao TF, Cheng HM, Liu ME, Wang TD, Yeh HI, Li YH, Liu PY, Yin WH, Hsieh IC, Wang CC, Chen CH, Chu PH, Lin SJ, Yeh SJ, Lin JL, Hwang JJ, Hung HF, Chen WJ, Hou CJY. 2023 Consensus of Taiwan Society of Cardiology on the Pharmacological Treatment of Chronic Heart Failure. *Acta Cardiol Sin* 2023;39(3):361-390. (IF:1.9)
33. ^{2,5}Chiang CH, Chen C, Fang SY, Lin SC, Chen JW, Chang TT*. Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease. *Life Sci* 2023;327:121863. (IF:6.1)
34. ^{2,5}Chien YS*, Weng CJ, Wu SJ, Li CH, Lin JC, Huang JL, Lin SF, Lin YJ, Hsieh YC*, Chen SA*. Levosimendan attenuates electrical alternans and prevents ventricular arrhythmia during therapeutic hypothermia in isolated rabbit hearts. *Heart Rhythm* 2023;20(5):744-753. (IF:5.5)
35. ⁵Chin CG, Chen YC, Lin YK, Lu YY, Cheng WL, Chung CC, Chen SA, Chen YJ*. Effect of macrophage migration inhibitory factor on pulmonary vein arrhythmogenesis through late sodium current. *Europace* 2023;25(2):698-706. (IF:6.1)
36. ^{2,5}Chin CG, Hsieh YC, Lin WS, Lin YJ, Chiou CW, Lin TH, Huang CL, Hung Y, Lin YK, Chang SL, Yeh TC, Lee HC, Lai WT, Hsieh MH*. An open-label randomized noninferior study of generic name and brand name of propafenone for rhythm control in patients with paroxysmal atrial fibrillation. *J Chin Med Assoc* 2023;86(5):472-478. (IF:3)
37. ^{2,5}Chiu HH, Chang SL*, Cheng HM, Chao TF, Lin YJ, Lo LW, Hu YF, Chung FP, Liao JN, Tuan TC, Lin CY, Chang TY, Kuo L, Liu CM, Tsai YN, Huang YT, Chang YL, Wung JC,

- Chen SA. Shared decision making for anticoagulation reduces anxiety and improves adherence in patients with atrial fibrillation. *BMC Med Inform Decis Mak* 2023;23(1):163. (IF:3.5)
38. ^{2,5}Chou RH, Yang SF, Wu CH, Tsai YL, Lu YW, Guo JY, Huang PH*, Lin SJ. Association between Premorbid Renin-Angiotensin-Aldosterone System Blockade and the Risk of Acute Kidney Injury in Critically Ill Patients. *Acta Cardiol Sin* 2023;39(5):709-719. (IF:1.9)
39. ^{2,5}Fan HY, Chien KL, Huang YT, Hsu JB, Chen YY, Lai EY, Su JY, Lu TP, Li HY, Hsu SY, Chen YC*. Hypertension as a Novel Link for Shared Heritability in Age at Menarche and Cardiometabolic Traits. *J Clin Endocrinol Metab* 2023;108(9):2389-2399. (IF:5.8)
40. ^{2,5}Fan HY, Huang YT, Chen YY, Hsu JB, Li HY, Su TC, Lin HJ, Chien KL*, Chen YC*. Systolic blood pressure as the mediator of the effect of early menarche on the risk of coronary artery disease: A Mendelian randomization study. *Front Cardiovasc Med* 2023;9:1023355. (IF:3.6)
41. ^{2,5}Fan HY, Lin WY, Lu TP, Chen YY, Hsu JB, Yu SL, Su TC, Lin HJ, Chen YC, Chien KL*. Targeted next-generation sequencing for genetic variants of left ventricular mass status among community-based adults in Taiwan. *Front Genet* 2023;13:1064980. (IF:3.7)
42. ²Fu YT, Kuo L, Yu WC*. Isolated transthyretin valvular amyloidosis. *Eur Heart J* 2023;44(29):2789-2789. (IF:39.3)
43. ²Ho IW, Huang CC*. Furosemide-induced haemolytic anaemia in an extreme elderly patient. *ESC Heart Fail* 2023;10:1449-1453. (IF:3.8)
44. ²Ho IW, Kuo MJ, Hsu PF, Lee IH, Hsu TF, Lin YJ, Huang CC*. The impacts of anemia burden on clinical outcomes in patients with out-of-hospital cardiac arrest. *Clin Cardiol* 2023;24-Oct:doi: 10.1002/clc.24175. (IF:2.7)
45. ^{1,5}Hsieh JC*, Shih H, Xin LL, Yang CC, Han CL. 12-lead ECG signal processing and atrial fibrillation prediction in clinical practice. *Technol Health Care* 2023;31(2):417-433. (IF:1.6)
46. ^{2,4}Hsieh MC, Yu WC, Weng CC, Chen WJ, Chen CK, Lee YC, Chen MH*. Elevated serum levels of T-cell immunoglobulin and mucin-domain containing molecule 3 in patients with systemic inflammation following COVID-19 vaccination. *J Chin Med Assoc* 2023;86(9):818-825. (IF:3)
47. ^{2,5}Hsu CC, Chen CC, Chou CY, Chen KH, Wang SF, Chang SL, Chang YL*. Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and advanced kidney disease. *J Thromb Thrombolysis* 2023;56(4):518-528. (IF:4)
48. ^{2,5}Hsu CY, Huang CY, Shih CM, Lin YW, Huang PH, Lin SJ, Liu CW, Lin CY, Lin FY*. Tumor Necrosis Factor Superfamily 14 (LIGHT) Restricts Neovascularization by Decreasing Circulating Endothelial Progenitor Cells and Function. *Int J Mol Sci* 2023;24(8):6997. (IF:5.6)
49. ²Huang JT, Sung SH, Hsu CP, Chiang CE, Yu WC, Cheng HM, Huang CH. TIMP-1 in the prognosis of patients who underwent coronary artery bypass surgery: a 12-year follow-up study. *Front Cardiovasc Med* 2023;10:1226449. (IF:3.6)
50. ^{2,5}Huang SH, Tsao HM*, Liao CF, Chen ZY, Chao TF, Chen SA*. Multimodality imaging assessment of the Biatrial remodeling of the burden of atrial high-rate episodes in patients with cardiac implanted electronic devices. *Int J Cardiol* 2023;371:175-183. (IF:3.5)

51. ^{2,5}Huang SS, Huang WC, Tsai CT, Chen YY, Lee SH, Lu TM*. Plasma asymmetric dimethylarginine is associated with vulnerable plaque and long-term outcomes in stable coronary artery disease. *Sci Rep* 2023;13(1):7541. (IF:4.6)
52. ^{2,5}Huang TC, Lo LW*, Chou YH, Lin WL, Chang SL, Lin YJ, Liu SH, Cheng WH, Liu PY, Chen SA. Renal denervation reverses ventricular structural and functional remodeling in failing rabbit hearts. *Sci Rep* 2023;13(1):8664. (IF:4.6)
53. ²Huang WC, Chen YY, Yang SY, Lai CF, Lai TS, Chen HY, Chen LW, Wang YJ, Cheng YL, Lang CL, Chen CF, Chang HF, Peng JK, Lin LY, Cheng HM, Hwu CM, Lu TM, Chueh JS, Lin YH, Wu VC*. Fat mass as an important predictor of persistent hypertension in patients with primary aldosteronism after adrenalectomy. *Hypertens Res* 2023;46(6):1375-1384. (IF:5.4)
54. ^{2,5}Huang WC, Hsieh SC, Wu YW, Hsieh TY, Wu YJ, Li KJ, Charng MJ, Chen WS, Sung SH, Tsao YP, Ho WJ, Lai CC, Cheng CC, Tsai HC, Hsu CH, Lu CH, Chiu YW, Shen CY, Wu CH, Liu FC, Lin YH, Yeh FC, Liu WS, Lee HT, Wu SH, Chang CC, Chu CY, Hou CJY*, Tsai CY. 2023 Taiwan Society of Cardiology (TSOC) and Taiwan College of Rheumatology (TCR) Joint Consensus on Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. *Acta Cardiol Sin* 2023;39(2):213-241. (IF:1.9)
55. ²Huang WM, Chang HC, Chen CN, Huang CJ, Yu WC, Cheng HM, Guo CY, Chiang CE, Chen CH, Sung SH*. Symptom-limited exercise capacity is associated with long-term survival. *Medicine (Baltimore)* 2023;102(39):e34948. (IF:1.6)
56. ²Huang WM, Chang HC, Lee CW, Huang CJ, Yu WC, Cheng HM, Guo CY, Chiang CE, Chen CH, Sung SH*. Association between spirometry pattern, left ventricular diastolic function, and mortality. *Eur J Clin Invest* 2023;53(10):e14043. (IF:5.5)
57. ^{1,5}Kao TW, Liao CW, Tsai CH, Chang YY, Pan CT, Chang CC, Lee BC, Huang WC, Huang KH, Lu CC, Lai TS, Chan CK, Chueh JS, Wu VC, Hung CS, Chen ZW*, Lin YH. Synergistic effect of albuminuria on atherosclerosis in patients with primary aldosteronism. *Ther Adv Chronic Dis* 2023;14:1–14. (IF:3.5)
58. ^{1,5}Kao TW, Huang CC*, Leu HB, Yin WH, Tseng WK, Wu YW, Lin TH, Yeh H, Chang KC, Wang JH, Wu CC, Chen JW. Inflammation and renal function decline in chronic coronary syndrome: a prospective multicenter cohort study. *BMC Cardiovasc Disord* 2023;23(1):564. (IF:2.1)
59. ^{2,5}Kario K*, Tomitani N, Wang TD, Park S, Li Y, Shin J, Tsoi K, Chen CH, Cheng HM, Siddique S, Turana Y, Buranakitjaroen P, Huynh MV, Nailes J, Sison J, Soenarta AA, Sogunuru GP, Sukonthasarn A, Tay JC, Teo BW, Verma N, Zhang YQ, Schlaich M, Nagai M, Fujiwara T, Hoshide S, Chia YC, Wang JG. Home blood pressure-centered approach - from digital health to medical practice: HOPE Asia Network consensus statement 2023. *Hypertens Res* 2023;46:2561-2574. (IF:5.4)
60. ^{2,5}Kuo CC, Chang HH, Leu HB, Chen IM, Chen PL, Lin SM, Chen YH*. Outcomes and Hemodynamic Performances of Transcatheter Aortic Valve Replacement with Two Generations of Self-Expanding Transcatheter Aortic Valves. *Acta Cardiol Sin* 2023;39(3):449-456. (IF:1.9)
61. ¹Kuo L, Shirai Y*. Optimal ablation strategy for idiopathic ventricular arrhythmia arising from right ventricular outflow tract: when to perform reversed-U curve technique?. *J Interv Card Electrophysiol* 2023;66(2):243-244. (IF:1.8)

62. ²Kuo MJ, Lin CY, Lin YJ*, Chang SL, Lo LW, Hu YF, Chung FP, Tuan TC, Chao TF, Liao JN, Chang TY, Kuo L, Wu CI, Liu CM, Liu SH, Chen SA. Insight of electrocardiographic and electrophysiological parameters on the left ventricular function in patients with ventricular arrhythmia from left ventricular summit. *J Cardiovasc Electrophysiol* 2023;34(5):1230-1240. (IF:2.7)
63. ²Kuo MJ, Ton ANK, Lo LW*, Lin YJ, Chang SL, Hu YF, Chung FP, Tuan TC, Chao TF, Liao JN, Chang TY, Lin CY, Kuo L, Wu CI, Liu CM, Cheng WH, Liu SH, Chhay C, Kao PH, Chen WT, Hsu CY, Chen SA*. Abnormal Conduction Zone Detected by Isochronal Late Activation Mapping Accurately Identifies the Potential Atrial Substrate and Predicts the Atrial Fibrillation Ablation Outcome After Pulmonary Vein Isolation. *Circ-Arrhythmia Electrophysiol* 2023;16(2):76-85. (IF:8.4)
64. ^{2,5}Lee AS, Sung YL, Pan SH, Sung KT, Su CH, Ding SL, Lu YJ, Hsieh CL, Chen YF, Liu CC, Chen WY, Chen XR, Chung FP, Wang SW, Chen CH, Mochly-Rosen D, Hung CL*, Yeh HI*, Lin SF. A Common East Asian aldehyde dehydrogenase 2*2 variant promotes ventricular arrhythmia with chronic light-to-moderate alcohol use in mice. *Commun Biol* 2023;6(1):610. (IF:5.9)
65. ²Lee DY, Chang TY*, Chang SL*, Lin YJ, Lo LW, Hu YF, Chung FP, Tuan TC, Chao TF, Liao JN, Lin CY, Kuo L, Liu CM, Chen SA. Clinical outcomes and structural remodelling after ablation of atrial fibrillation in heart failure with mildly reduced or mid-range ejection fraction. *ESC Heart Fail* 2023;10(1):177-188. (IF:3.8)
66. ²Lee DY, Chen T, Huang WC*, Chou RH, Wu CH*, Yang CY*, Lee CY, Lin CC, Tarng DC. Systemic vascular resistance predicts high-output cardiac failure in patients with high-flow arteriovenous fistula. *ESC Heart Fail* 2023;26-Oct: doi: 10.1002/ehf2.14563. (IF:3.8)
67. ²Lee DY, Huang CJ, Yeh WY, Sung SH, Chen CH, Cheng HM*. Improvement of clinical outcomes in patients undergoing peritoneal dialysis using hydroxymethylglutaryl-CoA reductase inhibitors: A systematic review and meta-analysis. *J Chin Med Assoc* 2023;86(2):155-165. (IF:3)
68. ²Lee HW, Huang CC*, Yang CY, Leu HB, Huang PH, Wu TC, Lin SJ, Chen JW. Renal function during hospitalization and outcome in Chinese patients with acute decompensated heart failure: A retrospective study and literature review. *Clin Cardiol* 2023;46(1):57-66. (IF:2.7)
69. ^{2,5}Lee YH, Hsieh MT, Chang CC, Tsai YL, Chou RH, Lu HHS*, Huang PH*. Improving detection of obstructive coronary artery disease with an artificial intelligence-enabled electrocardiogram algorithm. *Atherosclerosis* 2023;381:117238. (IF:5.3)
70. ²Li GY, Chen YY, Lin YJ*, Chien KL, Hsieh YC, Chung FP, Lo LW, Chang SL, Chao TF, Hu YF, Lin CY, Chen SA. Ablation of atrial fibrillation and dementia risk reduction during long-term follow-up: a nationwide population-based study. *Europace* 2023;25(5):euad109. (IF:6.1)
71. ²Li GY, Elimam AM, Lo LW*, Lin YJ, Chang SL, Hu YF, Chung FP, Chao TF, Lin CY, Liu CM, Liao JN, Ton AKN, Yugo D, Lin LD, Tuan TC, Kao PH, Liu SH, Chhay C, Kuo L, Cheng WH, Chen WT, Chen SA. Factors predicting the progression from paroxysmal to persistent atrial fibrillation despite an index catheter ablation. *J Cardiovasc Electrophysiol* 2023;34:2504-2513. (IF:2.7)

72. ^{2,5}Liao CW, Lin YT, Tsai CH, Chang YY*, Chen ZW, Lu CC, Pan CT, Chang CC, Lee BC, Chiu YW, Huang WC, Huang KH, Lai TS, Hung CS, Wu VC, Wu XM*, Lin YH*. Mineralocorticoid receptor antagonist treatment improved arterial stiffness in patients with primary aldosteronism: a cohort study compared with adrenalectomy. *Ther Adv Chronic Dis* 2023;14:2.04E+16. (IF:3.5)
73. ²Liao TWE, Li CH, Lin YJ, Chang SL, Hu YF, Chung FP, Chao TF, Liao JN, Yang HW, Lo MT, Chen SA*, Lo LW*. Fractal complexity alternations in paroxysmal atrial fibrillation patients with and without recurrence after pulmonary vein isolation. *Ann Noninvasive Electrocardiol* 2023;28(5):e13074. (IF:1.9)
74. ^{2,5}Lin CH, Lin CY*, Chung FP, Lin YJ, Chang SL, Lo LW, Hu YF, Chao TF, Liao JN, Chang TY, Tuan TC, Kuo L, Wu CI, Liu CM, Liu SH, Li GY, Kuo MJ, Weng CJ, Chen SA. Catheter ablation in Asian patients with atrial fibrillation and hypertrophic cardiomyopathy: electrophysiological characteristics of recurrence and long-term clinical outcomes. *Front Cardiovasc Med* 2023;10:1135230. (IF:3.6)
75. ^{2,5}Lin CJ, Chung CP*, Cheng HM, Liu CH, Hsu LC, Chi NF, Tang SC, Lee JT, Po HL, Jeng JS, Wang TD, Lee IH. The 2020 Taiwan Stroke Society guidelines for blood pressure control at the acute stage of ischemic stroke. *J Formos Med Assoc* 2023;122(2):98-105. (IF:3.2)
76. ^{2,5}Lin CP*, Huang PH, Chen CY, Tzeng IS, Wu MY, Chen JS, Chen JW, Lin SJ. Tributyrin Intake Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysm in LDLR^{-/-} Mice. *Int J Mol Sci* 2023;24(9):8008. (IF:5.6)
77. ²Lin CY, Chang TY, Hu YF*, Hsieh YC, Chen YJ, Yeh HI, Lin YJ, Chang SL, Lo LW, Chao TF, Chung FP, Liao JN, Tuan TC, Chen SA*. Epicardial electrical heterogeneity after amiodarone treatment increases vulnerability to ventricular arrhythmias under therapeutic hypothermia. *PLoS One* 2023;18(4):e0282943. (IF:3.7)
78. ²Lin CY, Chiang CH, Te ALD, Lin YJ*, Lo MT, Lin C, Chang SL, Lo LW, Hu YF, Chung FP, Tuan TC, Chao TF, Liao JN, Chen SA. Characterization and identification of atrial fibrillation drivers in patients with nonparoxysmal atrial fibrillation using simultaneous amplitude frequency electrogram transform. *J Cardiovasc Electrophysiol* 2023;34(3):536-545. (IF:2.7)
79. ^{2,5}Lin PL, Wu YW, Lin CF, Yeh HI, Chang WT, Charng MJ, Huang PH, Lin CC, Lin TH, Lin WW, Hsieh IC, Kuo FY, Chen CP, Li YH*. Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan. *J Atheroscler Thromb* 2023;30(9):1123-1131. (IF:4.4)
80. ^{2,5}Lin RA, Hsieh JT, Huang CC, Yang CY*, Lin YP, Tarng DC. Circulating Osteocalcin Fractions are Associated with Vascular Calcification and Mortality in Chronic Hemodialysis Patients. *Calcif Tissue Int* 2023;113:416-425. (IF:4.2)
81. ^{2,5}Lin Y, Chao TF, Tsai ML, Tseng CJ, Wang TH, Chang CH, Lin YS, Yang NI, Chu PH, Hung MJ, Wu VCC*, Chen TH*. Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4-5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study. *J Thromb Thrombolysis* 2023; Aug 21:doi: 10.1007/s11239-023-02885-9. (IF:4)
82. ²Liu CM, Chen YC, Hu YF*. Harnessing cell reprogramming for cardiac biological pacing. *J Biomed Sci* 2023;30(1):74. (IF:11)

83. ²Liu CM, Lin FJ, Chen YC, Lin YK, Lu YY, Chan CS, Higa S, Chen SA, Chen YJ*. Modulation of post-pacing action potential duration and contractile responses on ventricular arrhythmogenesis in chloroquine-induced long QT syndrome. *Eur J Pharmacol* 2023;941:175493. (IF:5)
84. ^{2,4}Liu SH, Chao TF*, Chan YH*, Liao N, Chen SA. Clinical outcomes of patients with incident atrial fibrillation diagnosed by cardiologists compared to non-cardiologists. *Eur J Intern Med* 2023;112:140-142. (IF:8)
85. ^{2,4}Liu SH, Chao TF*, Chan YH*, Liao JN, Chen TJ, Lip GYH, Chen SA. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study. *Europace* 2023;25:euad120. (IF:6.1)
86. ^{2,4}Liu SH, Chhay C, Hu YF*, Lin YJ, Chang SL, Lo LW, Chung FP, Tuan TC, Chao TF, Liao JN, Lin CY, Chang TY, Kuo L, Liu CM, Ton ANK, Yugo D, Chen SA. ABO Blood Groups as a Disease Marker to Predict Atrial Fibrillation Recurrence after Catheter Ablation. *J Pers Med* 2023;13(2):1064980. (IF:3.4)
87. ^{2,5}Lu YW, Tsai CT, Chou RH, Tsai YL, Kuo CS, Huang PH*, Lin SJ. Sex difference in the association of the triglyceride glucose index with obstructive coronary artery disease. *Sci Rep* 2023;13(1):9652. (IF:4.6)
88. ^{1,5}Lu YY, Chen YC, Lin YK, Chen SA, Chen YJ*. Electrical and Structural Insights into Right Ventricular Outflow Tract Arrhythmogenesis. *Int J Mol Sci* 2023;24(14):11795. (IF:5.6)
89. ^{2,5}Nademanee K*, Chung FP, Sacher F, Nogami A, Nakagawa H, Jiang CY, Hocini M, Behr E, Veerakul G, Smit JJ, Wilde AAM, Chen SA, Yamashiro K, Sakamoto Y, Morishima I, Das MK, Khongphatthanayothin A, Vardhanabhuti S, Haissaguerre M. Long-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry). *Circulation* 2023;147(21):1568-1578. (IF:37.8)
90. ^{2,5}Nagai M*, Dote K, Park S, Turana Y, Buranakitjaroen P, Cheng HM, Soenarta AA, Li Y, Kario K, HOPE Asia Network. Obstructive sleep apnea and non-dipper: epiphenomena or risks of Alzheimer's disease?: a review from the HOPE Asia Network. *Hypertens Res* 2023;24-Oct:doi: 10.1038/s41440-023-01440-6. (IF:5.4)
91. ^{2,5}Nguyen DSN, Chang SL*, Weng CJ, Wu FY, Chen SA. The appearance of new accessory pathway after the Cone procedure. *J Cardiovasc Electrophysiol* 2023;34:2617-2620. (IF:2.7)
92. ^{1,5}Ong KL*, Marklund M, Huang LP, Rye KA, Hui NCL, Pan XF, Rebholz CM, Kim H, Steffen LM, Westing ACV, Geleijnse JM, Hoogeveen EK, Chen YY, Chien KL, Fretts AM, Lemaitre RN, Imamura F, Forouhi NG, Wareham NJ, Birukov A, Jaeger S, Kuxhaus O, Schulze MB, Mello VDD, Tuomilehto J, Uusitupa M, Lindstroem J, Tintle N, Harris WS, Yamasaki K, Hirakawa Y, Ninomiya T, Tanaka T, Ferrucci L, Bandinelli S, KVirtanen J, Voutilainen A, Jayasena T, Thalamuthu A, Poljak A, Bustamante S, Sachdev PS, KSennII M, Rich SS, Tsai MY, Wood AC, Laakso M, Lankinen M, Yang XW, Sun L, Li HX, Lin X, Nowak C, Aernloev J, Riserus U, Lind L, Le Goff M, Samieri C, Helmer C, Qian F, Micha R, Tin A, Koettgen A, Boer IHD, Siscovick DS, Mozaffarian D, Wu JH. Association of omega 3 polyunsaturated fatty acids with incident chronic kidney disease: pooled analysis of 19 cohorts. *BMJ-British Medical Journal* 2023;380:e072909. (IF:107.7)

93. ^{2,5}Peng JY, Chen YH, Yen JH, Huang WM, Chen CN*. Effects of Exercise Training on Cognitive Function in Individuals With Heart Failure: A Meta-Analysis. *Phys Therapy* 2023;103(6):pzad027. (IF:3.8)
94. ^{2,5}Romiti GF, Corica B, Proietti M, Mei DA, Frydenlund J, Bisson A, Boriani G, Olshansky B, Chan YH, Huisman MV, Chao TF*, Lip GYH*. Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry. *EClinicalMedicine* 2023;63:102039. (IF:15.1)
95. ⁵Savelieva I*, Fumagalli S*, Kenny RA, Anker S, Benetos A, Boriani G, Bunch J, Dagres N, Dubner S, Fauchier L, Ferrucci L, Israel C, Kamel H, Lane DA, Lip GYH, Marchionni N, Obel I, Okumura K, Olshansky B, Potpara T, Stiles MK, Tamargo J, Ungar A, Kosiuk J, Larsen TB, Dinov B, Estner H, Garcia R, Costa FMM, Lampert R, Lin YJ, Chin A, Rodriguez HA, Strandberg T, Grodzicki T. EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRs), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). *Europace* 2023;25(4):1249-1276. (IF:6.1)
96. ^{2,5}Sung HP, Hsu CY, Lee YH, Lin PL, Liao CT, Chung FP, Ko SL, Huang CY, Lin KC, Chang HY*. Iron deficiency in Taiwanese patients with heart failure and reduced ejection fraction. *J Chin Med Assoc* 2023;86(8):725-731. (IF:3)
97. ^{2,5}Sweis JIG, Sweis NWG, Alnaimat F, Jansz J, Liao TWE, Alsakaty A, Azam A, Elmergawy H, Hanson HA, Ascoli C, Rubinstein I, Sweiss N*. Immune-mediated lung diseases: A narrative review. *Front Med* 2023;10:1160755. (IF:3.9)
98. ^{2,5}Tang SY, Lee YC, Tseng CW, Huang PH, Kuo KL*, Tarng DC*. Granulocyte Colony-Stimulating Factor Improves Endothelial Progenitor Cell-Mediated Neovascularization in Mice with Chronic Kidney Disease. *Pharmaceutics* 2023;15(10):2380. (IF:5.4)
99. ^{2,5}Trang NN, Lee TW, Kao YH, Chao TF, Lee TI*, Chen YJ. Ketogenic diet modulates cardiac metabolic dysregulation in streptozocin-induced diabetic rats. *J Nutr Biochem* 2023;111:109161. (IF:5.6)
100. ²Tsai CT, Chan YH, Liao JN, Chen TJ, Lip GYH, Chen SA, Chao TF*. Risk of Incident Atrial Fibrillation and Subsequent Use of Oral Anticoagulants in Patients with Dementia. *Thromb Haemost* 2023;30-Oct:doi: 10.1055/a-2184-7506. (IF:6.7)
101. ²Tsai CT, Chao TF*. Incidence and Risk Factors for Pregnancy-Associated Venous Thromboembolism: Are There Differences between East and West? *Thromb Haemost* 2023;123:911-912. (IF:6.7)
102. ^{2,5}Tsai TY, Lo LW*, Lin WL, Chou YH, Cheng WH, Liu SH, Yang CCH, Kuo TBJ, Chen SA. Neural mechanism facilitating PM2.5-related cardiac arrhythmias through cardiovascular autonomic and calcium dysregulation in a rat model. *Sci Rep* 2023;13(1):16016. (IF:4.6)
103. ^{2,5}Tsai TY, Lo LW*, Cheng WH, Liu SH, Lin EJ, Chang SL, Hu YF, Chung FP, Liao ON, Tuan TC, Chao ZF, Lin CY, Chang TY, Liu CM, Chheng C, Hermanto DY, An TN, Elimam AMM, Huang TC, Lee PS, Lee CH, Chen SA*. 10-Year Outcomes of Patients With Non-Paroxysmal Atrial Fibrillation Undergoing Catheter Ablation. *Circ J* 2023;87(1):84-91. (IF:3.3)

104. ^{2,5}Tsai WC*, Lin YJ*, Chang SL, Lo LW, Hu YF, Chao TF, Chung FP, Liao JN, Chang TY, Tuan TC, Kuo L, Wu CI, Liu CM, Liu SH, Kuo MR, Chen SA. High-density characterization of the sinus rhythm: a new functional substrate map of scar-related atrial tachycardia. *J Interv Card Electrophysiol* 2023;66:1631-1639. (IF:1.8)
105. ^{2,4}Tsai YL, Lee CW, Huang WM, Cheng HM, Yu WC, Chen CH, Sung SH*. Surgery for severe mitral regurgitation: The etiology matters. *J Chin Med Assoc* 2023;86(10):869-875. (IF:3)
106. ²Tseng CH, Tseng CL, Chen HS, Chen PL, Huang CJ*. Clinical characteristics of neutropenic patients under antithyroid drug: Twelve-year experience in a medical center. *J Chin Med Assoc* 2023;86(9):826-834. (IF:3)
107. ^{2,5}Ueng KC, Chiang CE*, Chao TH, Wu YW, Lee WL, Li YH, Ting KH, Su CH, Lin HJ, Su TC, Liu TJ, Lin TH, Hsu PC, Wang YC, Chen ZC, Jen HL, Lin PL, Ko FY, Yen HW, Chen WJ, Hou CJY. 2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome. *Acta Cardiol Sin* 2023;39(1):4-96. (IF:1.9)
108. ^{2,5}Wang CC*, Chang WT, Lin YH, Tzeng BH, Chao TH, Hung CL, Wu YW, Tsai CH, Lin WW, Chang KC, Chang HY, Yu WC, Wang WH, Cheng CI, Wang TD, Hou CJY, Chen WJ. 2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis. *Acta Cardiol Sin* 2023;39(4):511-543. (IF:1.9)
109. ^{2,5}Wang JC, Tsai SH*, Chien WC, Chung CH, Lin SJ, Chen YT, Huang PH*. Association between gout and abdominal aortic aneurysm. *J Cardiol* 2023;82(4):274-278. (IF:2.5)
110. ^{2,5}Wang JC, Tsai SH*, Tsai HY, Lin SJ, Huang PH*. Hyperuricemia exacerbates abdominal aortic aneurysm formation through the URAT1/ERK/MMP-9 signaling pathway. *BMC Cardiovasc Disord* 2023;23(1):55. (IF:2.1)
111. ²Wang WT, Li CY*, Chang YT, Bai YM, Tsai SJ, Chen TJ, Chiou SH, Chen MH*. Proton-pump inhibitors are associated with an increased risk of asthma: A nationwide nested case-control study. *Allergy Asthma Proc* 2023;44(5):345-353. (IF:2.8)
112. ²Wang Y, Kuo L*. Uncommon Cause of Myocarditis After COVID-19 Protein Subunit Vaccine. *Korean Circ J* 2023;53(2):109-111. (IF:2.9)
113. ^{2,5}Wei JH, Lee WJ, Luo JL, Huang HL, Wang SC, Chou RH, Huang PH, Lin SJ. Vertical Sleeve Gastrectomy Offers Protection against Disturbed Flow-Induced Atherosclerosis in High-Fat Diet-Fed Mice. *Int J Mol Sci* 2023;24(6):5669. (IF:5.6)
114. ^{2,5}Weng CJ, Chung FP*. Wide QRS Complex Tachycardia after Catheter Ablation of Bundle Branch Reentrant Tachycardia: What is the Mechanism? *Acta Cardiol Sin* 2023;39(4):651-653. (IF:1.9)
115. ^{2,5}Wu SJ, Lo LW*, Chung FP, Lin YJ, Chang SL, Hu YF, Hsieh YC, Li CH, Tuan TC, Chao TF, Liao JN, Lin CY, Chang TY, Kuo L, Liu CM, Liu SH, Wu C, Weng CJ, Kuo MJ, Li GY, Huang YS, Bautista JA, Siow YK, Ngoc NDS, Chen SA*. Comparison of Long-Term Clinical Outcomes Between Segmental and Circumferential Pulmonary Vein Isolation in Patients Undergoing Repeat Atrial Fibrillation Ablation. *Circ J* 2023;87(12):1750-1756. (IF:3.3)
116. ^{2,5}Yang YL, Chen SC, Wu CH, Huang SS, Chan WL, Lin SJ, Chou CY, Chen JW, Pan JP, Charng MJ, Chen YH, Wu TC, Lu TM, Hsu PF, Huang PH, Cheng HM, Huang CC, Sung SH, Lin YJ, Leu HB*. Sex and age differences of major cardiovascular events in patients after percutaneous coronary intervention. *J Chin Med Assoc* 2023;86(12):1046-1052. (IF:3)

Endocrinology and Metabolism

1. ^{2,5}Armstrong ND*, Srinivasasainagendra V, Ammous F, Assimes TL, Beitelshes AL, Brody J, Cade BE, Chen YDI, Chen H, de Vries PS, Floyd JS, Franceschini N, Guo XQ, Hellwege JN, House JS, Hwu CM, Kardina SLR, Lange EM, Lange LA, Mcdonough CW, Montasser ME, O'Connell JR, Shuey MM, Sun X, Tanner RM, Wang Z, Zhao W, Carson AP, Edwards TL, Kelly TN, Kenny EE, Kooperberg C, Loos RJJ, Morrison AC, Motsinger-Reif A, Psaty BM, Rao DC, Redline S, Rich SS, Rotter JI, Smith JA, Smith AV, Irvin MR, Arnett DK. Whole genome sequence analysis of apparent treatment resistant hypertension status in participants from the Trans-Omics for Precision Medicine program. *Front Genet* 2023;14:1278215. (IF:3.7)
2. ^{2,5}Chang LH, Chu CH, Huang CC, Lin LY*. Soluble tumor necrosis factor receptor type 1 predicts cardiorenal outcomes and better associated with distinct cardiovascular or renal outcomes than precedential renal or cardiovascular events in type 2 diabetes mellitus. *Ther Adv Endocrinol Metab.* 2023 Oct 29;14:20420188231207345. (IF:3.8)
3. ^{2,5}Chang TT, Li SY, Lin LY, Chen C, Chen JW. Macrophage inflammatory protein-1 β as a novel therapeutic target for renal protection in diabetic kidney disease. *Biomed Pharmacother.* 2023 May;161:114450. (IF: 7.5)
4. ^{2,5}Chen C, Lin LY, Chen JW, Chang TT. CXCL5 suppression recovers neovascularization and accelerates wound healing in diabetes mellitus. *Cardiovasc Diabetol.* 2023 Jul 7;22(1):172. (IF: 9.3)
5. ^{2,4}Chen CY, Leu HB, Wang SC, Tsai SH, Chou RH, Lu YW, Tsai YL, Kuo CS, Huang PH, Chen JW, Lin SJ. Inhibition of Trimethylamine N-Oxide Attenuates Neointimal Formation Through Reduction of Inflammasome and Oxidative Stress in a Mouse Model of Carotid Artery Ligation. *Antioxidants & Redox Signaling.* 2023 Jan;38(1-3):215-233. (IF: 6.6)
6. ^{2,5}Chen F, Wang X, Jang SK, Quach BC, ..., Sheu WH, Sims M, ...et al. Multi-ancestry transcriptome-wide association analyses yield insights into tobacco use biology and drug repurposing. *Nat Genet* 2023;55:291-300. (IF: 30.8)
7. ^{2,5}Chen LC, Huang WC, Peng KY, Chen YY, Li SC, Syed Mohammed Nazri SK, Lin YH, Lin LY, Lu TM, Kim JH, Azizan EA, Hu J, Li Q, Chueh JS, Wu VC; TAIPAI Study Groupi. Identifying KCNJ5 Mutation in Aldosterone-Producing Adenoma Patients With Baseline Characteristics Using Machine Learning Technology. *JACC Asia* 2023;3:664-75. (IF:1.8)
8. ^{2,5}Chiu CH, Hsuan CF, Lin SH, Hung YJ, Hwu CM, Hee SW, Lin SW, Fong SW, Hsieh PC, Yang WS, Lin WC, Lee HL, Hsieh ML, Li WY, Lin JW, Hsu CN, Wu VC, Chuang GT, Chang YC, Chuang LM. ER ribosomal-binding protein 1 regulates blood pressure and potassium homeostasis by modulating intracellular renin trafficking. *J Biomed Sci.* 2023 Feb 19;30(1):13. (IF: 11.0)
9. ^{2,5}Hang JF, Chen JY, Kuo PC, Lai HF, Lee TL, Tai SK, Kuo CS*, Chen HS, Li WS, Li CF. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases. *Mod Pathol* 2023;36:100242. (IF:7.5)
10. ^{2,5}Ho LJ, Sheu WHH, Lo SH, Yeh YP, Hwu CM, Huang CN, Hsieh CH, Kuo FC*. Unhealthy lifestyle associated with increased risk of macro- and micro-vascular

- comorbidities in patients with long-duration type 2 diabetes: results from the Taiwan Diabetes Registry. *Diabetol Metab Syndr* 2023;15:38. (IF:4.8)
11. ^{2,5}Hsu CY, Sheu WHH, Lee IT*. Brain-derived neurotrophic factor associated with kidney function. *Diabetol Metab Syndr* 2023;15(1):16. (IF: 4.8)
 12. ^{2,5}Huang CC, Shen HC, Lin R, Yang YY*, Chang YC, Liao TL, Huang SF, Lin HC, Hou MC. Preservation of vascular endothelial glycocalyx and barrier by activation of adenosine A2A receptor (A2AR) improved renal dysfunction in cirrhotic rats. *J Pharmacol Sci* 2023;152:50-60. (IF: 3.5)
 13. ²Huang CJ, Lee LH, Cheng CP, Chen HS, Hwu CM, Tang KT, Shih CW, Yeh CC, Wang FF*, Yang CC. Analytical validation of an inductively coupled plasma mass spectrometry method for urinary iodine concentration measurements in Taiwan. *J Formos Med Assoc.* 2023;122:757-65. (IF: 3.2)
 14. ²Huang CJ, Lee LH, Cheng CP, Yao SF, Chen HS, Hwu CM, Tang KT, Wang FF, Shih CW, Yang CC*, Huang WS*. Measurements of elemental iodine in soy sauces in Taiwan using a modified microplate method. *Front Endocrinol (Lausanne).* 2023;14:1058695. (IF: 5.2)
 15. ²Huang CJ, Li JZ, Hwu CM, Chen HS, Wang FF, Yeh CC*, Yang CC*. Iodine Concentration in the Breast Milk and Urine as Biomarkers of Iodine Nutritional Status of Lactating Women and Breastfed Infants in Taiwan. *Nutrients* 2023;15:4125. (IF:5.9)
 16. ²Huang CJ, Li JZ, Hwu CM, Chen HS, Yeh CC, Wang FF*, Yang CC*. Determination of the Elemental Iodine in Human Breast Milk by Inductively Coupled Plasma mass Spectrometry. *Biol Trace Elem Res* 2023 Jul 28 (IF: 3.9).
 17. ²Huang CJ, Lu CH Lu; Shih KC*. Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B/C and Chronic Kidney Disease: An Open-Label, Phase I Study. *Eur J Drug Metab Pharmacokinet* 2023;48:665-74. (IF: 1.9)
 18. ^{2,4}Huang WC, Chen YY, Yang SY, Lai CF, Lai TS, Chen HY, Chen L, Wang YJ, Cheng YL, Lang CL, Chen CF, Chang HF, Peng JK, Lin LY, Cheng HM, Hwu CM, Lu TM, Chueh JS, Lin YH, Wu VC*. Fat mass as an important predictor of persistent hypertension in patients with primary aldosteronism after adrenalectomy. *Hypertens Res.* 2023;46:1375-84 (IF: 5.4)
 19. ^{2,5}Jan YT, Tsai PS, Huang WH, Chou LY, Huang SC, Wang JZ, Lu PH, Lin DC, Yen CS, Teng JP, Mok GSP, Shih CT, Wu TH*. Machine learning combined with radiomics and deep learning features extracted from CT images: a novel AI model to distinguish benign from malignant ovarian tumors. *Insights into Imaging.* 2023;14:68. (IF: 4.7)
 20. ^{1,5}Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, ...Farsani SF*, Paterno E, Nunez J. EMPRISE Europe and Asia Study Group. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. *Diabetes Metab.* 2023 Mar;49(2):101418. (IF: 7.2)
 21. ^{2,5}Kim DJ, Sheu WH, Chung WJ, Yabe D, Ha KH, Nangaku M, Tan EC, Node K, Yasui A, Lei W, Lee S, Saarelainen L, Deruaz-Luyet A, Kyaw MH, Seino Y*; EMPRISE East Asia Study Group. Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study. *J Diabetes Investig.* 2023 Mar;14(3):417-428. (IF: 3.2)

22. ^{1,5}Lim LL, Lau ESH, Kong APS, ..., Sheu WHH, et al. Gender-associated cardiometabolic risk profiles and health behaviors in patients with type 2 diabetes: a cross-sectional analysis of the Joint Asia Diabetes Evaluation (JADE) program. *Lancet Reg Health West Pac.* 2022 Dec 19;32:100663. (IF: 7.1)
23. ^{2,5}Lin WC*, Chen WC, Wang PW, Chan YC, Chang YH, Chen HS, Chen ST, Chen WC, Cheng KL, Chi SY, Chiang PL, Chou CK, Chou FF, Huang SC, Liu FH, Luo SD, Tseng FY, Wang CY, Wang WH, Wu MH. 2022 Taiwan clinical multicenter expert consensus and recommendations for thyroid radiofrequency ablation. *Ultrasonography* 2023;42:357-75. (IF: 3.1)
24. ^{2,5}Liu PYT, Lin FJ, Yeh CF, Hsiao YC, Hsuan CF, Chang WT, Kao HL, Jeng JS, Wu YW, Hsieh IC, Fang CC, Wang KY, Chang KC, Lin TH, Sheu WHH, Li YH, Yin WH, Yeh HI, Chen JW, Wu CC*. Association of Major Adverse Cardiac Events and Beta-Blockers in Patients with and without Atherosclerotic Cardiovascular Disease: Long-Term Follow-Up Results of the T-SPARCLE and T-PPARCLE Registry in Taiwan. *J Clin Med* 2023;12(6):2162. (IF:3.9)
25. ^{2,5}Lu YW, Tsai CT, Chou RH, Tsai YL, Kuo CS, Huang PH, Lin SJ. Sex difference in the association of the triglyceride glucose index with obstructive coronary artery disease. *Scientific Reports.* 2023;13:9652. (IF: 4.6)
26. ^{2,5}Luo YY, Chang YP*, Zhao Z, Xia J, Xu CC, Bee YM, Li XY, Sheu WHH, McGill M, Chan SP, Deodat M, Suastika K, Thy KN, Chen LM, Kong APS, Chen W, Deerochanawong C, Yabe D, Zhao W, Lim S, Yao X, Ji L. Device-supported automated basal insulin titration in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Lancet Reg Health West Pac* 2023;35:100746. (IF: 7.1)
27. ^{2,4}Ou SM, Tsai MT, Lee KH, Tseng WC, Yang CY, Chen TH, Bin PJ, Chen TJ, Lin YP, Sheu WH, Chu YC*, Tarng DC*. Prediction of the risk of developing end-stage renal diseases in newly diagnosed type 2 diabetes mellitus using artificial intelligence algorithms. *BioData Min* 2023;16:8. (IF: 4.5)
28. ²Pan LH, Yen CC, Huang CJ, Ng XN, Lin LY. Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience. *Front Endocrinol (Lausanne)* 2023;14: 1134643. (IF: 5.2)
29. ^{1,5}Parameswaran R*, de Jong MC, Kit JLW, Sek K, Nam TQ, Thang TV, Khue NT, Aye TT, Tun PM, Cole T, Miller JA, Villa M, Khiewvan B, Sirinvaravong S, Sin YL, Muhammad R, Jap TS, Agrawal A, Rajput R, Fernando R, Sumanatilleke M, Suastika K, Shong YK, Lang B, Bartalena L, Yang SP*. 2021 Asia-Pacific Graves' Disease Consortium Survey of Clinical Practice Patterns in the Management of Graves' Disease. *Endocrine* 2023;79(1):135-142. (IF:3.7)
30. ^{2,5}Sheen YJ, Wang JM, Tsai PF, Lee WJ, Hsu YC, Wang CY, Sheu WH*. Accuracy of Point-of-Care Blood Glucometers in Neonates and Critically Ill Adults. *Clin Ther.* 2023 Jul;45(7):643-648. (IF: 3.2)
31. ^{2,4}Sheu WH*. Toward better diabetes care: Exploration and implementation. *J Diabetes Investig.* 2023;14:640-4. (IF: 3.2)
32. ²Su GY, Ning NX, Lin KH, Hwu CM* Low-Density Lipoprotein Cholesterol is not a Major Determinant of High Sensitivity C-Reactive Protein Levels in People without Known Diabetes Mellitus. *Metab Syndr Relat Disord* 2023;21:567-72. (IF: 2.1)

33. ^{1,5}Sun PC*, Kuo CD, Wei SH, Lin HD. Microvascular reactivity using laser Doppler measurement in type 2 diabetes with subclinical atherosclerosis. *Lasers Med Sci* 2023;38(1):80. (IF:2.1)
34. ^{2,5}Ting YH, Wang YF, Lin YC, Chen HT, Lin KH, Tarng DC*, Tseng WC*. Chronic hypokalemia and painful diffuse bone lesions. *Kidney Int* 2023;104(1):207-208. (IF:19.6)
35. ^{1,5}Tobias DK, Merino J, Ahmad A, Aiken C, Benham JL, Bodhini D, ..., Sheu WH, Speake C, Stanislawski MA, Steenackers N, ..., Franks PW*. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. *Nat Med* 2023 Oct;29(10):2438-2457. (IF: 82.9)
36. ^{2,4}Tseng CH, Tseng CL, Chen HS, Chen PL, Huang CJ*. Clinical characteristics of neutropenic patients under antithyroid drug: Twelve-year experience in a medical center. *J Chin Med Assoc.* 2023;86:826-834. (IF: 3.0)
37. ^{2,5}Williamson A, Norris DM, Yin X, ..., Hwu CM, Mohlke KL*, Wheeler E*, O'Rahilly S*, Fazakerley DJ*, Langenberg C*. Genome-wide association study and functional characterization identifies candidate genes for insulin-stimulated glucose uptake. *Nat Genet* 2023;55:973-83. (IF: 30.8)
38. ^{2,5}Wu SY, Wu CY, Lin LY, Chen YH, Huang HY, Lai YL, Lee SY*. Systemic antibiotics adjuvants to scaling and root planing in type 2 diabetic and periodontitis individuals: Systematic review with network meta-analysis. *Jpn Dent Sci Rev* 2023;59:167-78. (IF: 6.6)
39. ²Wu TH, Su GY, Liu TY, Wang HT, Hwu CM*. Urinary acrolein protein conjugates-to-creatinine ratio is positively associated with diabetic peripheral neuropathy in patients with type 2 diabetes mellitus. *Endocr Connect* 2023;12:e230253. (IF:2.9)
40. ²Yeh YK, Yen FS, Hwu CM*. Diet and exercise are a fundamental part of comprehensive care for type 2 diabetes. *J Diabetes Investig.* 2023;14:936-9. (IF: 3.2)
41. ^{2,5}Yen FS, Chang SH, Wei JC, Shih YH, Hwu CM*. Respiratory Outcomes of Insulin Use in Patients with COPD: A Nationwide Population-Based Cohort Study. *Pharmaceuticals (Basel).* 2023;16:643. (IF: 4.6)
42. ^{2,5}Yen FS, Hou MC, Liu JS, Hsu CC, Hwu CM*. Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes. *Front Med (Lausanne)* 2023;9:962337. (IF: 3.9)
43. ^{2,5}Yen FS, Hou MC, Pan CW, Liu JS, Hsu CC*, Hwu CM*. The Risk of Severe Hypoglycemia and Mortality in Patients With Type 2 Diabetes and Discharged With Acute Liver Injury. *Diabetes Care* 2023;46:20-7. (IF:16.2)
44. ^{2,5}Yen FS, Lee PC, Hwu CM*. Is a low-carbohydrate, high-fat diet feasible for people with type 2 diabetes and nonalcoholic fatty liver disease? *J Diabetes Investig* 2023;14:930-2. (IF: 3.2)
45. ^{2,5}Yen FS, Wei JC, Hung YT, Hsu CY, Hwu CM*, Hsu CC. Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes. *Front Microbiol* 2023;14:1118000. (IF: 5.2)
46. ^{2,5}Yen FS, Wei JC, Shih YH, Hsu CC, Hwu CM*. Impact of individual microvascular disease on the risks of macrovascular complications in type 2 diabetes: a nationwide population-based cohort study. *Cardiovasc Diabetol* 2023;22:109. (IF: 9.3)

47. ^{2,5}Yen FS, Wei JCC, Liu JS, Hwu CM*, Hsu CC*. Parental Income Level and Risk of Developing Type 2 Diabetes in Youth. *JAMA Netw Open* 2023;6(11):e2345812. (IF:13.8)
48. ^{2,5}Yen FS, Wei JC, Yu TS, Hung YT, Hsu CC, Hwu CM*. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes. *JAMA Netw Open* 2023; 6:e2348431. (IF:13.8)
49. ^{2,5}Yen FS, Wei JCC, Yip HT, Hsu CC*, Hwu CM*. Metformin use and the risks of herpes zoster and postherpetic neuralgia in patients with type 2 diabetes. *J Med Virol* 2023;95:e28278. (IF:12.7)
50. ^{2,5}Ying TH#, Huang CJ#, Hsieh CJ, Wu PJ, Yeh CC, Hung PK, Chang WH, Wu MH, Hung H, Chang JW, Wang CT, Arcega RD, Mahmudiono T, Lee CC*, Chen HL*. Potential Factors Associated with the Blood Metal Concentrations in Reproductive Age Women in Taiwan. *Exposure and Health* 2023 March 10 (IF: 6.7)

Infectious Diseases

1. ²Chuang C, Lee KC, Wang YP, Lee PC, Chang TE, Huang YH, Lin YT*, Hou MC*. High carriage rate of extended-spectrum β -lactamase Enterobacterales and diarrheagenic *Escherichia coli* in healthy donor screening for fecal microbiota transplantation. *Eur J Clin Microbiol Infect Dis* 2023;42:1103-13. (IF:4.5)
2. ^{2,5}DeLeo FR*, Porter AR, Kobayashi SD, Freedman B, Hao MJ, Jiang JP, Lin YT, Kreiswirth BN, Chen L, Goldberg JB. Interaction of multidrug-resistant hypervirulent *Klebsiella pneumoniae* with components of human innate host defense. *mBio* 2023;14:e0194923. (IF:6.4)
3. ^{2,5}Estephan L, Lin YC, Lin YT, Chen YH, Pan SC, Hsieh SM, Torkehagen PF, Weng YJ, Cheng HY, Estrada JA, Waits A, Chen CR, Lien CE*. Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial. *Vaccine* 2023;41:3497-505. (IF:5.5)
4. ²Huang SF, Wu AYJ, Lee SSS, Huang YS, Lee CY, Yang TL, Wang HW, Chen HJ, Chen YC, Ho TS, Kuo CF*, Lin YT*. COVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosis. *J Microbiol Immunol Infect* 2023;56:442-54. (IF:7.4)
5. ^{2,5}Ku RH, Li LH, Liu YF, Hu EW, Lin YT, Lu HF, Yang TC*. Implication of the σ E Regulon Members OmpO and σ N in the Δ ompA299-356-Mediated Decrease of Oxidative Stress Tolerance in *Stenotrophomonas maltophilia*. *Microbiol Spectr* 2023;11:e0108023. (IF:3.7)
6. ^{2,5}Lai YH, Lee YC, Chen IR, Lin SN, Chang YL, Lu CC, Wu PF, Lin YT*. Prognostic factors for poor outcomes in patients with severe COVID-19 treated with remdesivir plus dexamethasone in Taiwan. *J Microbiol Immunol Infect* 2023;56(6):1207-1213. (IF:7.4)
7. ^{2,5}Lee MH*, Wu PF, Chen TI, Chan C, Lin HH, Huang YH, Chen HY, Lin YT, Chen CJ. Tenofovir use is associated with a decreased risk of hepatocellular carcinoma among men with HIV irrespective of coinfection status. *JHEP Rep* 2023;5:100634. (IF:8.3)
8. ²Lin YT*, Chuang C, Chou SH, Juan CH, Yang TC, Kreiswirth BN, Chen L*. Emergence of OXA-48-producing hypervirulent *Klebsiella pneumoniae* strains in Taiwan. *Eur J Clin Microbiol Infect Dis* 2023 Dec 7. doi: 10.1007/s10096-023-04733-3. (IF:4.5)

9. ^{2,5}Shin MH, Hsu HS, Chien JY, Huang CK, Kuo LC, Shun TM, Lin YT, Yeh YC*. Association between microcirculation in spontaneous breathing trial and extubation success. *Microvasc Res* 2023;148:104552. (IF:3.1)
10. ^{1,5}Tsai CC, Lin JC, Chen PC, Liu EYM, Tsai YK, Yu CP, Li JJ, Wang CH, Fung CP, Lin FM, Chang FY*, Siu LK*. A 20-Year Study of Capsular Polysaccharide Seroepidemiology, Susceptibility Profiles, and Virulence Determinants of *Klebsiella pneumoniae* from Bacteremia Patients in Taiwan. *Microbiol Spectr* 2023;11:e0035923. (IF:3.7)
11. ^{1,5}Wu HY, Chang PH, Huang YS, Tsai CS, Chen KY, Lin IF, Hsieh WH, Tsai WL, Chen JA, Yang TL, Lee CY, Ho TS, Wang HW, Huang SF, Wu AYJ, Chen HJ, Chen YC, Chen WC, Tseng CH, Lin PC, Yang CH, Hong PL, Lee SSJ*, Chen YS, Liu YC, Wang FD. Recommendations and guidelines for the diagnosis and management of Coronavirus Disease-19 (COVID-19) associated bacterial and fungal infections in Taiwan. *J Microbiol Immunol Infect* 2023;56:207-35. (IF:7.4)
12. ^{2,5}Wu HY, Lin YT, Tsai WC, Chiu YL, Ko MJ, Yang JY, Pai MF, Hsu HS, Hsu SP, Peng YS, Liao CH*. Microbiota analysis in the hemodialysis population- Focusing on Enterobacteriaceae. *J Microbiol Immunol Infect* 2023;56:311-23. (IF:7.4)

Nephology

1. ^{2,5}Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators (Tarnag DC). Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. *Ann Intern Med.* 2023;176(12):1606-1616. (IF:39.2)
2. ^{2,5}Chang TT*, Li SY, Lin LY, Chen C, Chen JW*. Macrophage inflammatory protein-1 β as a novel therapeutic target for renal protection in diabetic kidney disease. *Biomed Pharmacother* 2023;161:114450. (IF:7.5)
3. ^{2,5}Chen IT, Wang TY, Yang CY*. An eighth note. Perfusion. *Am J Med Sci* 2023;366(6):E103-E104. (IF:3.1)
4. ²Chen TH, Ho Y, Tai HL, Chu YC, Lin YP, Yang CY, Tseng WC, Ou SM, Tsai MT, Chen JY, Wu TH, Lee KH, Chen FY, Li SY, Lin CC, Tarnag DC*. Survival benefit of a third dose of the COVID-19 vaccine among hemodialysis patients: A prospective cohort study. *J Microbiol Immunol Infect.* 2023 Dec;56(6):1198-1206. (IF:7.4)
5. ^{2,5}Guo BC, Kuo KL, Huang JW, Chen CH, Tarnag DC*, Lee TS*. Di-(2-ethylhexyl) Phthalate Limits the Lipid-Lowering Effects of Simvastatin by Promoting Protein Degradation of Low-Density Lipoprotein Receptor: Role of PPAR γ -PCSK9 and LXR α -IDOL Signaling Pathways. *Antioxidants* 2023;12(2):477. (IF:7)
6. ^{2,5}Huang YJ, Hung CC, Hsu PC, Lee PY, Tsai YA, Hsin YC, Lee XT, Chou CC, Chen ML, Tarnag DC, Lee YH*. Astrocytic aryl hydrocarbon receptor mediates chronic kidney disease-associated mental disorders involving GLT1 hypofunction and neuronal activity enhancement in the mouse brain. *Glia* 2023;71(4):1057-1080. (IF:6.2)
7. ^{2,5}Jasuja S*, Gallieni M, Jha V, Vachharajani T, Bhalla AK, Tan J, Tan CS, Basnet NB, Herath N, An HPH, Kim YS, Kim Y, Sampathkumar K, Sahay M, Ramachandran R, Alexander S, Bhargava V, Balasubramaniam J, Voss D, Ogbac FE, Gunawan A, Goh BL, Lin CC, Khan J,

- Shiham I, Ayub H, Hein MA, Iqbal S, Srisawat N, Gao BH, Sajiv C, Wilkinson C, Pichthida T, Rana DS, Sagar G, Bahl A, Tawakley S, Gaur M. Practice of dialysis access interventional nephrology procedures in the Asia-Pacific region: Getting lay of the land. *Nephrology* 2023;28:672-681. (IF:2.5)
8. ^{2,5}Kao TW, Liu YS, Yang CY, Lee OKS*. Mechanotransduction of mesenchymal stem cells and hemodynamic implications. *Chin J Physiol* 2023;66(2):55-64. (IF:1.8)
 9. ^{2,5}Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M, Tangri N, Waikar SS, Więcek A, Cheung M, Jadoul M, Winkelmayr WC, Wheeler DC; for Conference Participants (Tarnng DC). Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int* 2023;104(4):655-680. (IF:19.6)
 10. ^{2,5}Kuo CW, Chen DH, Tsai MT, Lin CC, Cheng HW, Tsay YG, Wang HT*. Pyruvate kinase M2 modification by a lipid peroxidation byproduct acrolein contributes to kidney fibrosis. *Front Med* 2023;10:1151359. (IF:3.9)
 11. ^{2,5}Kuo FC, Wu TH, Loong CC, Lin NC, Ou SM, Chen CY*. The strategy of diminishing age gap effect on different donor-recipient combinations in living donor kidney transplantation. *J Chin Med Assoc* 2023;86(1):65-71. (IF:3)
 12. ^{2,5}Lai YT, Huang HL, Hsieh CC, Lin CH, Yang JC, Tsou HH, Lin CC, Li SY, Chan HL, Liu WS*. The Effects of Yoga Exercise on Blood Pressure and Hand Grip Strength in Chronic Stroke Patients: A Pilot Controlled Study. *Int J Environ Res Public Health* 2023;20(2):1108. (IF:)
 13. ^{2,4}Lee DY, Chen T, Huang WC*, Chou RH, Wu CH*, Yang CY, Lee CY, Lin CC, Tarnng DC. Systemic vascular resistance predicts high-output cardiac failure in patients with high-flow arteriovenous fistula. *ESC Heart Fail* 2023; Oct 26:doi: 10.1002/ehf2. 14563. (IF:3.8)
 14. ^{2,4}Lee HW, Huang CC*, Yang CY, Leu HB, Huang PH, Wu TC, Lin SJ, Chen JW. Renal function during hospitalization and outcome in Chinese patients with acute decompensated heart failure: A retrospective study and literature review. *Clin Cardiol* 2023;46(1):57-66. (IF:2.7)
 15. ²Li SY, Chen CY, Tsai MT, Lin NC, Liu CS*, Lin CC. Hybrid Method for Peritoneal Dialysis Catheter Insertion: A New Technique for Improved Outcomes and Reduced Costs. *Am J Nephrol* 2023;54:349-358. (IF:4.2)
 16. ^{2,5}Lin RA, Hsieh JT, Huang CC, Yang CY*, Lin YP, Tarnng DC. Circulating Osteocalcin Fractions are Associated with Vascular Calcification and Mortality in Chronic Hemodialysis Patients. *Calcif Tissue Int* 2023;113:416-425. (IF:4.2)
 17. ^{2,5}Liu WS, Lin CH, Tan AC, Lai YT, Liu TY, Chan HL, Li SY, Chen CF, Chen YT, Chen TH, Chen FY, Ho Y, Tsou HH*, Lin CC*. The Associations between Erythropoietic Response with Inflammation Markers and Perfluorinated Chemicals in Hemodialysis Patients. *Healthcare* 2023;11(3):442. (IF:2.8)
 18. ^{2,5}Liu WS, Lin CH, Tsai CY, Wang HT, Li SY, Liu TY, Tan AC, Tsou HH, Tseng KH, Lin CC*. Double Filtration Plasmapheresis with Polyvinyl Alcohol-Based Membrane Lowers Serum Inflammation and Toxins in Patients with Hyperlipidemia. *Bioengineering-Basel* 2023;10(1):89. (IF:4.6)
 19. ^{2,5}Ni Z, Liang X, Wu CC, Jin K, Kim YL, Lu KC, Chan TM, Fukagawa M, Kinoshita J, Nagai

- C, Kojima M, Yu X*; Orchestra Study Group (Tarng DC). Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism. *Kidney Int Rep* 2023 29;8(11):2294-2306. (IF:6)
20. ²Ou SM, Chao CJ, Tsai MT, Lee KH, Tseng WC, Bin PJ, Lin YP, Hsu CY, Tarng DC. Echocardiographic features of left ventricular dysfunction and outcomes in chronic kidney disease. *Heart* 2023;109(2):134-142. (IF:5.7)
 21. ²Ou SM, Tsai MT, Lee KH, Tseng WC, Yang CY, Chen TH, Bin PJ, Chen TJ, Lin YP, Sheu WHH, Chu YC*, Tarng DC*. Prediction of the risk of developing end-stage renal diseases in newly diagnosed type 2 diabetes mellitus using artificial intelligence algorithms. *BioData Min* 2023;16(1):8. (IF:4.5)
 22. ^{2,5}Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL; FIDELIO-DKD Investigators (Tarng DC). Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. *Diabetes Care* 2022;45:888-897. *Diabetes Care* 2023 1;46(9):1721. (IF:16.2)
 23. ^{2,5}Tang CF, Wu MY, Wei YH, Ho Y, Kuo KL*. Leukocyte 8-hydroxy-2'- deoxyguanosine as an oxidative stress marker to predict cardiovascular events and death in chronic hemodialysis patients. *J Chin Med Assoc* 2023;86:911-6. (IF:3)
 24. ^{2,5}Tang SY, ²Chen TH, Kuo KL, Huang JN, Kuo CT*, Chu YC*. Using artificial intelligence algorithms to predict the overall survival of hemodialysis patients during the COVID-19 pandemic: A prospective cohort study. *J Chin Med Assoc* 2023;86:1020-7. (IF:3)
 25. ^{2,5}Tang SY, Lee YC, Tseng CW, Huang PH, Kuo KL*, Tarng DC*. Granulocyte Colony-Stimulating Factor Improves Endothelial Progenitor Cell-Mediated Neovascularization in Mice with Chronic Kidney Disease. *Pharmaceutics* 2023;15:2380. (IF:5.4)
 26. ^{2,5}Ting YH, Wang YF, Lin YC, Chen HT, Lin KH, Tarng DC*, Tseng WC*. Chronic hypokalemia and painful diffuse bone lesions. *Kidney Int* 2023;104(1):207-8. (IF:19.6)
 27. ^{2,5}Tsai CY*, Li KJ, Shen CY, Lu CH, Lee HT, Wu TH, Ng YY, Tsao YP, Hsieh SC, Tarng DC, Yu CL*. Decipher the Immunopathological Mechanisms and Set Up Potential Therapeutic Strategies for Patients with Lupus Nephritis. *Int J Mol Sci* 2023;24(12):10066. (IF:5.6)
 28. ^{2,5}Tsai LW, Shih CM, Li SY, Tseng SH, Dubey R*, Wu MS*. Susceptibility of Developing Renal and Lung Cancer in Polycystic Kidney Disease Patients: An Evidence in Reaching Consensus. *Eur J Cancer Care* 2023;2023:5036299. (IF:2.1)
 29. ^{2,5}Tsai MR, Lee CY, Yang CY*, Tarng DC. An eighth note. *Perfusion-UK* 2023;38(1):200-2. (IF:1.2)
 30. ²Tsai MT, Yang RB, Ou SM, Tseng WC, Lee KH, Yang CY, Chang FP, Tarng DC*. Plasma Galectin-9 Is a Useful Biomarker for Predicting Renal Function in Patients Undergoing Native Kidney Biopsy. *Arch Pathol Lab Med* 2023;147(2):167-76. (IF:4.6)
 31. ²Wang TY, Chang FP, Yang AH, Ka SM, Chen A, Hsieh JT, Chen FY, Lee TL, Tseng PY, Tsai MT, Li SY, Yang CY*, Chen JY, Lin CC, Tarng DC. Key pathological features characterize minimal change disease-like IgA nephropathy. *PLoS One* 2023;18:e0288384. (IF:3.7)
 32. ²Yang CH, Chen YA, Bin PJ, Ou SM*, Tarng DC*. Associations of the Serum Total Carbon Dioxide Level with Long-Term Clinical Outcomes in Sepsis Survivors. *Infect Dis Ther*

2023;12:687-701. (IF:5.4)

33. ^{2,5}Yen CC, Hsu PC, Lin CC, Chen SC, Hsiao CY, Hwang SJ*. Effect of far-infrared radiation therapy on von Willebrand factor in patients with chronic kidney disease. *Front Med* 2023;10:1268212. (IF:3.9)
34. ^{2,5}Yi TW, Smyth B, Di Tanna GL, Arnott C, Cardoza K, Kang A, Pollock C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Neal B, Wheeler DC, Cannon CP, Zhang H, Zinman B, Perkovic V, Levin A, Mahaffey KW, Jardine M; CREDENCE Trial Investigators (Lin CC). Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. *Am J Kidney Dis* 2023;82:84-96.e1. (IF=13.2)

Hematology

1. ^{2,4}Hsu TL, Tsai CK, Liu CY, Yeh CM, Lin FL, Hsiao LT, Liu YC, Wang HY, Ko PS, Lin TA, Chen WC, Chen PM, Liu JH, Gau JP, Liu CJ*. Risk Factors and Outcomes of Stem Cell Mobilization Failure in Multiple Myeloma Patients. *Transfus Med Hemother* 2023;50:39-50. (IF:2.2)
2. ^{2,5}Hu YW, Yeh CM, Liu CJ, Chen TJ, Huang NCL, Chou YJ*. Adapted Diabetes Complications Severity Index and Charlson Comorbidity Index in predicting all-cause and cause-specific mortality among patients with type 2 diabetes. *BMJ Open Diab Res Care* 2023;11:e003262. (IF:4.1)
3. ^{2,5}Jiang JG, Liu CJ, Yeh CM, Yang CF, Liu YC, Wang HY, Ko PS, Chen PM, Yu YB, Gau JP, Tsai CK*. Prognostic factors in patients with bone marrow hemophagocytosis and its association with hematologic malignancies *Hematol Oncol* 2023;41: 67-77. (IF:3.3)
4. ^{2,5}Kim WS*, Fukuhara N, Yoon DH, Yamamoto K, Uchida T, Negoro E, Izutsu K, Terui Y, Nakajima H, Ando K, Suehiro Y, Kang HJ, Ko PS, Nagahama F, Sonehara Y, Nagai H, Tien HF, Kwong YL, Tobinai K. Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study. *Blood Adv* 2023;7:4903-12. (IF:7.6)
5. ^{2,4}Lai TY, Hu YW, Wang TH, Chen JP, Shiao CY, Huang PI, Lai IC, Tseng LM, Huang N, Liu CJ*. Association of Radiation Dose to Cardiac Substructures with Major Ischaemic Events Following Breast Cancer Radiotherapy. *Eur Heart J* 2023;44:4796-807. (IF:39.3)
6. ^{2,5}Lee CH, Lin TC, Yao M, Hsiao LT, Ko BS, Liu CJ, Chen TY*. Allogeneic hematopoietic stem cell transplantation for B-cell lymphoma in Taiwan. *Cancer Med* 2023;12:21761-9. (IF:4)
7. ^{2,4}Lin WY, Tsai CK, Yeh CM, Chian T, Liu YC, Wang HY, Ko PS, Lin TA, Hsiao LT, Chen PM, Gau JP, Liu CJ*. Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients. *Cancer Med* 2023;12:3013-26.(IF:4)
8. ^{2,5}Mehra R, Shah, Liu CJ, Plouffe KR, Wang X, Mannan R, Cao X, Chinnaiyan AM, Tomlins SA, Udager AM*. Highly Recurrent IDH1 Mutations in Prostate Cancer With Psammomatous Calcification. *Mod Pathol* 2023;36:100146. (IF:7.5)
9. ^{2,5}Song YQ, Tilly H, Rai S, Zhang HL, Jin J, Goto H, Terui Y, Shin HJ, Kim WS, Cao JN, Feng JF, Eom HS, Kim TM, Tsai XCH, Gau JP, Koh H, Zhang LL, Song YP, Yang Y, Li W, Huang H, Ando K, Sharman JP, Sehn LH, Bu LL, Wang X, Jiang YW, Hirata J, Lee CL, Zhu

- J*, Izutsu K. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. *Blood* 2023;141:1971-81. (IF:20.3)
10. ²Wang HY, Yang CF, Lin CH, Hsiao LT, Ko PS, Liu YC, Chiou TJ, Chen PM, Liu JH, Gau JP, Liu CJ*. Long- term outcomes of frontline intensification in primary CNS lymphoma: A real-world single- center experience. *Cancer Med* 2023;12:8089-101. (IF:4.0)
 11. ²Wang HY, Yang FC, Yang CF, Liu YC, Ko PS, Li CJ, Tsai CK, Chung YL, Chen NJ*. Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment- naïve diffuse large B- cell lymphoma. *Exp Hematol Oncol* 2023;12:35. (IF:11.4)
 12. ²Wang YH, Wu WC, Hsiao LT, Ma SH, Chen CC, Ho YH*. Acquired hemophilia A in a Taiwanese patient with bullous pemphigoid. *Int J Rheum Dis* 2023;26:1838-9. (IF:2.5)
 13. ^{2,5}Wu WC, Huang CC, Tsai YF, Lin YS, Feng CJ, Chen YJ, Chen, Lai JL, Chao TC, Liu CY*, Tseng LM. The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis. *Breast Cancer Res Treat* 2023;198:113-22. (IF:3.8)
 14. ^{2,5}Wu WC*, Chen MH. Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib. *Front Oncol* 2023;10:1031396. (IF:4.7)

Allergy, Immunology and Rheumatology

1. ^{2,5}Chen CH, Chen HA, Liao HT, Chen CH*. Hydroxychloroquine exposure reduces the risk of cardiovascular disease events in patients with hypertension or diabetes mellitus. *Clin Exp Rheumatol.* 2023;41:2230-8. (IF:4.8)
2. ^{2,5}Chen CW, Ou TS, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang YW, Lin YZ, Chao Y, Wang LW*, Teng HW*. Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability. *Clin Colorectal Canc* 2023;22:267-79. (IF:3.4)
3. ²Chen MH, Chuang HC, Yeh YC, Chou CT*, Tan TH*. Dual-specificity phosphatases 22-deficient T cells contribute to the pathogenesis of ankylosing spondylitis. *BMC Med* 2023;21:46. (IF:9.3)
4. ^{1,5}Chen YH, Chen WY, Yu CL, Tsai CY, Hsieh SC*. Gouty arthritis involves impairment of autophagic degradation via cathepsin D inactivation-mediated lysosomal dysfunction that promotes apoptosis in macrophages. *Biochim Biophys Acta-Mol Basis Dis* 2023;1869(6):166703. (IF:6.2)
5. ^{2,5}Chiou YR, Chang YS, Su CF, Li TH, Lai CC, Hwang DK, Wu FY, Chang YF*. Risks of posterior segment ocular ischaemic events in patients with systemic lupus erythematosus: a population-based cohort study in Taiwan. *Br J Ophthalmol* 2023;107(11):1687-1692. (IF:4.1)
6. ^{2,5}Fang PJ, Kuo PH, Chen WL, Kao TW, Wu LW, Yang HF, Peng TC*. Prevalence of Ideal Cardiovascular Health Metrics among Young Asian Adults over 5 Years of Follow-Up. *Nutrients* 2023;15(3):645. (IF:5.9)
7. ^{2,4}Hsieh MC, Yu WC, Weng CC, Chen WJ, Chen CK, Lee YC, Chen MH*. Elevated serum

- levels of T-cell immunoglobulin and mucin-domain containing molecule 3 in patients with systemic inflammation following COVID-19 vaccination. *J Chin Med Assoc* 2023;86:818-25. (IF:3)
8. Hsieh TY, Chen MH, Wu CC, Hong WJ, Lu CH, Lu CC, Lu LY, Hsieh SC, Tsai CY, Wu CS*, Taiwan Vasculitis Study Grp. Rituximab induction and reinduction in granulomatosis with polyangiitis and microscopic polyangiitis: A retrospective multicenter study in Taiwan. *Int J Rheum Dis* 2023;26:2441-2449. (IF:2.5)
 9. Huang WC, Hsieh SC, Wu YW, Hsieh TY, Wu YJ, Li KJ, Charng MJ, Chen WS, Sung SH, Tsao YP, Ho WJ, Lai CC, Cheng CC, Tsai HC, Hsu CH, Lu CH, Chiu YW, Shen CY, Wu CH, Liu FC, Lin YH, Yeh FC, Liu WS, Lee HT, Wu SH, Chang CC, Chu CY, Hou CJY*, Tsai CY. 2023 Taiwan Society of Cardiology (TSOC) and Taiwan College of Rheumatology (TCR) Joint Consensus on Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. *Acta Cardiol Sin* 2023;39(2):213-241. (IF:1.9)
 10. ^{2,5}Khosasih V, Liu KM, Huang CM*, Liou LB, Hsieh MS, Lee CH, Tsai CY, Kuo SY, Hwa SY, Yu CL, Chang CH, Lin CJ, Hsieh SC, Cheng CY, Chen WM, Chen LK, Chuang HP, Chen YT, Tsai PC, Lu LS, H'ng WS, Zhang YF, Chen HC, Chen CH, Lee MTM, Wu JY*. A Functional Polymorphism Downstream of Vitamin A Regulator Gene CYP26B1 Is Associated with Hand Osteoarthritis. *Int J Mol Sci* 2023;24(3):3021. (IF:5.6)
 11. ²Liao HT*, Tsai CY. Cytokines and regulatory T cells in ankylosing spondylitis. *Bone Joint Res* 2023;12(2):133-137. (IF:4.6)
 12. ^{2,5}Lin TM, Hsu HC, Shen YC, Chang YS, Chen WS, Lee HY, Chang CK, Kuo TT, Chen SC, Chen JH, Chang CC*. GALTectomy increases the risk of allergic rhinitis: A nationwide population-based cohort study. *Allergy* 2023;78(6):1663-1665. (IF:12.4)
 13. ^{1,5}Tang H, Chang DM, Chu CC*. Keratoderma blennorrhagica in a patient without arthritis. *Int J Rheum Dis* 2023;26:2585-2586. (IF:2.5)
 14. ^{2,5}Tsai MK, Chen YL, Chen HC, Liu FC, Chang DM, Lu CC*. IgG4-related tubulointerstitial nephritis. *Ann Rheum Dis* 2023;():-. (IF:27.4)
 15. ^{2,5}Tsao YP, Tseng FY, Chao CW, Chen MH, Yeh YC, Abdulkareem BO, Chen SY, Chuang WT, Chang PC, Chen IC, Wang PH, Wu CS, Tsai CY, Chen ST*. NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression. *J Clin Invest* 2023;133(3):e157272. (IF:15.9)
 16. ^{2,5}Yen YN, Garrido-Cumbrera M, Sun YS, Chen CH, Lai CC, Tsai HC, Chen WS, Liao HT, Tsao YP, Tsai CY*, Chou CT. The Taiwanese Map of Axial Spondyloarthritis: Living with the Condition. *Med Lith* 2023;59(11):1962. (IF:2.6)

Transfusion Medicine

1. ³Aldoss I, Khaled SK, Wang X, Palmer J, Wang Y, Wagner JR, Clark MC, Simpson J, Paul J, Vyas V, Chien SH, Stein A, Pullarkat V, Salhotra A, Al Malki MM, Aribi A, Sandhu K, Thomas SH, Budde LE, Marcucci G, Brown CE, Forman SJ. Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL. *Clin Cancer Res* 2023;29:742-53. (IF:11.5)
2. ^{2,5}Chao TC, Tsai YF, Liu CY, Lien PJ, Lin YS, Feng CJ, Chen YJ, Lai JI, Hsu CY, Lynn JJ, Huang CC*, Tseng LM*. Prevalence of *PIK3CA* mutations in Taiwanese patients with breast

- cancer: a retrospective next-generation sequencing database analysis. *Front Oncol* 2023;13:1192946. (IF:4.7)
3. ^{2,5}Chen BF, Tsai YF, Lien PJ, Lin YS, Feng CJ, Chen YJ, Cheng HF, Liu CY, Chao TC, Lai JI, Tseng LM*, Huang CC*. Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan. *Breast Cancer* 2023;9-Dec:doi: 10.1007/s12282-023-01524-8. (IF:4)
 4. ^{2,5}Cheng HF, Tsai YF, Liu CY, Hsu CY, Lien PJ, Lin YS, Chao TC, Lai JI, Feng CJ, Chen YJ, Chen BF, Chiu JH, Tseng LM*, Huang CC*. Prevalence of *BRCA1*, *BRCA2*, and *PALB2* genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study. *Breast Cancer Res* 2023;25(1):152. (IF:7.4)
 5. ^{2,5}Chiu YN, Hsu CY, Lien PJ, Chao TC, Liu CY, Lin YS, Wang YL, Tsai YF*, Tseng LM. Impacts of HER2 immunohistochemical scores on response and outcomes of HER2-positive breast cancers after neoadjuvant therapy. *J Chin Med Assoc* 2023;86(4):409-417. (IF:3)
 6. ^{2,5}Hou MH, Lee CY, Ho CY, Yu TY, Hung GY, Huang FL, Chiou TJ, Liu CY, Yen HJ*. Donor lymphocyte infusion for prophylaxis and treatment of relapse in pediatric hematologic malignancies after allogeneic hematopoietic stem cell transplant. *J Chin Med Assoc* 2023;86(11):991-1000. (IF:3)
 7. ^{2,5}Hsu TL, Tsai CK, Liu CY, Yeh CM, Lin FL, Hsiao LT, Liu YC, Wang HY, Ko PS, Lin TA, Chen WC, Chen PM, Liu JH, Gau JP, Liu CJ*. Risk Factors and Outcomes of Stem Cell Mobilization Failure in Multiple Myeloma Patients. *Transfus Med Hemother* 2023;50(1):39-50. (IF:2.2)
 8. ^{2,5}Huang CC, Tsai YF, Liu CY, Lien PJ, Lin YS, Chao TC, Feng CJ, Chen YJ, Lai JI, Cheng HF, Chen BF, Hsu CY, Chiu JH, Tseng LM*. Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast Cancer. *Cancers* 2023;15(18):4475. (IF:5.2)
 9. ^{2,5}Lai JI*, Kuo TH, Huang KJ, Chai LMX, Lee MH, Liu CY, Tsai YF, Huang CC, Tseng LM, Hsu CC*, Chao TC. Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients. *Oncologist* 2023;23-Nov: oyad304. (IF:5.8)
 10. ²Liu CY*. Understanding gastric adenocarcinoma: Insights from immunoprofiling. *J Chin Med Assoc* 2023;86(9):780-780. (IF:3)
 11. ^{2,5}Rau KM, Shun SC, Hung SH, Chou HL, Ho CL, Chao TC, Liu CY, Lien CT, Hong MY, Wu CJ, Tsai LY, Jane SW, Hsieh RK*. Management of cancer-related fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment. *Jpn J Clin Oncol* 2023;53(1):46-56. (IF:2.4)
 12. ^{2,5}Tseng LM, Huang CC, Tsai YF, Chen JL, Lai J, Lien PJ, Lin YS, Feng CJ, Chen YJ, Chiu JH, Hsu CY, Liu CY*. Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers. *Transl Oncol* 2023;38:101782. (IF:5)
 13. ^{2,5}Tseng LM, Lau KY, Chen JL, Chu PY, Huang TT, Lee CH, Wang WL, Chang YY, Huang CT, Huang CC, Chao TC, Tsai YF, Lai JI, Dai MS, Liu CY*. Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model. *Exp Cell Res* 2023;429(1):113652. (IF:3.7)

14. ^{2,5}Wang SF, Lin YS, Yeh WY, Chang YL, Chiang CE, Chen CH, Tseng LM, Lee HC, Liu CY*, Cheng HM*. The Clinical Benefits of Antiresorptive Agents in Patients with Primary Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis. *J Clin Endocrinol Metab* 2023;108(11):E1433-E1447. (IF:5.8)
15. ^{2,5}Wu WC, Huang CC, Tsai YF, Lin YS, Feng CJ, Chen YJ, Lai JI, Chao TC, Liu CY*, Tseng LM*. The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis. *Breast Cancer Res Treat* 2023;198(1): 113-122. (IF:3.8)

General Medicine

1. ^{2,5}Chen CY, Leu HB, Wang SC, Tsai SH, Chou RH, Lu YW, Tsai YL, Kuo CS, Huang PH*, Chen JW, Lin SJ*. Inhibition of Trimethylamine N-Oxide Attenuates Neointimal Formation Through Reduction of Inflammation and Oxidative Stress in a Mouse Model of Carotid Artery Ligation. *Antioxid Redox Signal* 2023;38):215-33. (IF:6.6)
2. ^{2,4}Fu CC, Chen YJ*, Su CW, Wei CY, Chu CJ, Lee PC, Huo TI, Huang YH, Huang HC, Wu JC, Hou MC. The outcomes and prognostic factors of patients with hepatocellular carcinoma and Child-Turcotte-Pugh class B. *J Chin Med Assoc* 2023;86:876-84 (IF:3)
3. ^{2,4}Fu CC, Wei CY, Chu CJ, Lee PC, Huo TI, Huang YH, Chao Y, Hou MC, Wu JC, Su CW*. The outcomes and prognostic factors of patients with hepatocellular carcinoma and normal serum alpha fetoprotein levels. *J Formos Med Assoc* 2023;122:593-602. (IF:3.2)
4. ^{2,5}Ho SY, Liu PH, Hsu CY, Huang YH, Lei HJ, Liao JI, Su CW, Hou MC, Huo TI*. Surgical resection versus transarterial chemoembolization for patients with hepatocellular carcinoma beyond Milan criteria: prognostic role of tumor burden score. *Sci Rep* 2023;13:13871 (IF:4.6)
5. ^{2,5}Ho SY, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Hou MC, Huo TI*. Comparison of four albumin-based liver reserve models (ALBI/EZ-ALBI/PALBI/PAL) against MELD for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *Cancers* 2023;15:1925. (IF:5.2)
6. ^{2,5}Ho SY, Liu PH, Hsu CY, Tseng HT, Huang YH, Su CW, Hou MC, Huo TI*. Albumin-based liver reserve models vs. MELD 3.0 in prognostic prediction for hepatocellular carcinoma patients with renal insufficiency. *Int J Mol Sci* 2023;24:16987. (IF:5.6)
7. ^{2,5}Ho SY, Yuan MH, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Wang CL, Hou MC, Huo TI*. Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. *Scand J Gastroenterol* 2023;58:61-9 (IF:1.9)
8. ^{2,5}Kao WY, Tan ECH*, Lee HL, Huang YH, Huo TI, Chang CC, Chiou JF, Hou MC, Wu JC, Su CW*. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy. *Aliment Pharmacol Ther* 2023;57:1299-312. (IF:7.6)
9. ^{2,4}Liao JI, Ho SY, Liu PH, Hsu CY, Huang YH, Su CW, Hou MC, Huo TI*. Prognostic prediction for patients with hepatocellular carcinoma and ascites: role of albumin-bilirubin (ALBI) grade and easy (EZ)-ALBI grade. *Cancers* 2023;15:753. (IF:5.2)
10. ^{2,5}Liao YL, Wang TJ*, Su CW, Liang SY, Liu CY, Fan JY. Efficacy of a decision support intervention on decisional conflict related to hepatocellular cancer treatment: A randomized controlled trial. *Clin Nurs Res* 2023;32:233-43. (IF:1.7)

11. ²Liu SH, Chhay C, Hu YF, Lin YJ, Chang SL, Lo LW, Chung FP, Tuan TC, Chao TF, Liao JN, Lin CY, Chang TY, Kuo L, Liu CM, Ton AN, Yugo D, Chen SA. ABO Blood Groups as a Disease Marker to Predict Atrial Fibrillation Recurrence after Catheter Ablation. *J Pers Med*. 2023 Feb 17;13(2):355. (IF=3.4)
12. ²Liu SH, Chao TF, Chan YH, Liao JN, Chen SA. Clinical outcomes of patients with incident atrial fibrillation diagnosed by cardiologists compared to non-cardiologists. *Eur J Intern Med*. 2023 Jun;112:140-142. (IF=8.0)
13. ²Liu SH, Chao TF, Chan YH, Liao JN, Chen TJ, Lip GYH, Chen SA. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study. *Europace*. 2023 May 5;25(5):euad120. (IF=6.1)
14. ^{2,5}Lu YW, Tsai CT, Chou RH, Tsai YL, Kuo CS, Huang PH*, Lin SJ. Sex difference in the association of the triglyceride glucose index with obstructive coronary artery disease. *Sci Rep* 2023;13(1):9652. (IF:4.6)
15. ^{2,4}Luan CH, Su PS, Chu CJ*, Lin CC, Su CW, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC. Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response. *J Chin Med Assoc* 2023;86:795-805. (IF:3)
16. ²Pun CK, Chang CC, Chuang CL, Huang HC*, Hsu SJ*, Huang YH, Hou MC, Lee FY. Dual angiotensin receptor and neprilysin inhibitor reduced portal pressure through peripheral vasodilatation and decreasing systemic arterial pressure in cirrhotic rats. *J Chin Med Assoc* 2023;86:786-94. (IF:3)
17. ^{2,5}Shyr BU, Yeh YT, Teng WN, Liu CS, Chen CH, Huang LJ, Tseng LM, Ma H. Minimally Required Personal Protective Equipment during Local Anesthesia Surgery in COVID-19: A Simulation Study. *Plast Reconstr Surg Glob Open* 2023;11:e4792. (IF:1.5)
18. ²Su CW*. Stronger Neo-Minophagen C (SNMC): A stronger adjuvant for TACE? *Adv Digest Med* 2023;10:5-7. (IF:0.3)
19. ²Tsai YL, Lee CW, Huang WM, Cheng HM, Yu WC, Chen CH, Sung SH*. Surgery for severe mitral regurgitation: The etiology matters. *J Chin Med Assoc* 2023;86:869-75. (IF:3)
20. ^{2,4}Tseng YH, Liu CH, Lee CY, Chiu NC, Su CW*. Splenic artery pseudoaneurysm as a fatal complication for acute pancreatitis. *Adv Digest Med* 2023;10:110-3. (IF:0.3)

Endoscopy Center For Diagnosis and Treatment

1. ²Chang TE, Lee KC, Lee PC, Wang YP, Lin YT, Huang HC, Luo JC, Ho HL, Huang YH, Hou MC; Task Force for Precision Medicine in Gut Microbial Therapy. Assuring safety of fecal microbiota transplantation in the COVID-19 era: A single-center experience. *JGH Open* 2023;7:765-71. (IF:1.7)
2. ^{2,4}Chen, YJ, Hou, MC, Yang, TC, Lee, PC, Wang, YP, Huang, YH, & Lee, FY (2023). Effectiveness of betadine-coating gastrostomy tube to reduce peristomal infection after percutaneous endoscopic gastrostomy: a randomized controlled trial. *BMC gastroenterology*, 23(1), 155. (IF:2.4)
3. ^{2,5}Chiu HC, Liu CA*, Tseng HS, Ling K, Tsai YC, Huang HE, Wu PS, Lee RC. Predictors of

- technical success of percutaneous transhepatic common bile duct stone removal: is it only a matter of stone size?. *Eur Radiol* 2023;33(10):6872-6882. (IF:5.9)
4. ^{2,4}Chuang C., Lee, KC., Wang, YP, Lee, PC, Chang, TE, Huang, YH, Lin, YT, & Hou, MC (2023). High carriage rate of extended-spectrum β -lactamase Enterobacterales and diarrheagenic *Escherichia coli* in healthy donor screening for fecal microbiota transplantation. *European journal of clinical microbiology & infectious diseases* : official publication of the European Society of Clinical Microbiology, 42(9), 1103–1113.
 5. ^{2,5}Kim, JS, Chen, MH, Wang, HE, Lu, CL, Wang, YP*, & Zhang, B*. (2023). Inflammatory Bowel Disease and Neurodegenerative Diseases. *Gut and liver*, 17(4), 495–504. (IF:3.4)
 6. ^{2,4}Lee KC*, Wu PS, Lin HC*. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. *Clin Mol Hepatol* 2023;29(1):77-98. (IF:8.9)
 7. ^{2,4}Li CJ, Chang TE, Hou MC*, Huang YH, Lee PC, Chang NW, Chen YJ, Lee FY. Lockdown period during SARS COVID-19 endemic outbreak in Taiwan did not cause an increase of the complications nor mortality of patients received endoscopic retrograde cholangiopancreatography: A single-center retrospective study. *J Chin Med Assoc* 2023;86(2):147-154. (IF:3)
 8. ^{2,4}Pan YL, Wu PS*, Chen JH, Chen LY, Fang WL, Chau GY, Lee KC*, Hou MC. Early cholecystectomy following percutaneous transhepatic gallbladder drainage is effective for moderate to severe acute cholecystitis in the octogenarians. *Arch Gerontol Geriatr* 2023;106:104881. (IF:4)
 9. ²Wang YP, Zhang B*, Wang HE, Bai YM, Tsai SJ, Chen TJ, Chen MH*. Risk of Attempted Suicide Among Patients With IBD: A Nationwide Longitudinal Follow-up Study. *Dis Colon Rectum* 2023;66(9):E938-E945. (IF:4.1)
 10. ^{2,4}Yang TC, Chen WC, Hou MC*, Chen PH, Lee PC, Chang CY, Lu HS, Chen YJ, Hsu SJ, Huang HC, Luo JC, Huang YH, Lee FY. Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial. *Gut* 2023; Dec 14:gutjnl-2023-330419. (IF:24.5)

Holistic and Multidisciplinary Medicine

1. ²Chen TH, Chen MH, Hung YP, Chiang NJ, Huang KH, Lin YH, Lin RW, Chao Y, Li AFY, Yu HY, Hwang HE, Yeh YC, Wang YC*, Fang WL*. Elevated PD-L1 Expression and Microsatellite Instability in Elderly Patients With Gastric Cancer. *J Immunother* 2023;46(3):111-119. (IF:3.9)
2. ^{2,5}Chen WT, Li CH, Chou YH, Lin WL, Lin YJ, Chang SL, Hu YF, Chung FP, Liao JN, Tuan TC, Chao TF, Lin CY, Chang TY, Kuo L, Liu CM, Liu SH, Cheng WH, An TN, Elimam AMM, Chheng C, Nguyen TCK, Ahliah I, Kuo MR, Kao PH, Chen SA*, Lo LW*. Post-ablation augmentation of skin sympathetic nerve activity predicts a poor outcome of idiopathic ventricular arrhythmias. *J Cardiol* 2023;81(5):434-440. (IF:3.115)
3. ^{2,5}Fu CC, Wei CY, Chu CJ, Lee PC, Huo TI, Huang YH, Chao Y, Hou MC, Wu JC, Su CW*. The outcomes and prognostic factors of patients with hepatocellular carcinoma and normal serum alpha fetoprotein levels. *J Formos Med Assoc* 2023;122(7):593-602. (IF:3.2)
4. ²Hsu CH, Chen PL, Chen HP, Chan YJ. Outcomes of corticosteroid treatment in critical Ill

- adult patients with respiratory viruses-related community acquired pneumonia - a propensity-matched case control study. *J Microbiol Immunol Infect* 2023;56(4):757-765. (IF:7.4)
5. ²Hsu TL, Tsai CK, Liu CY, Yeh CM, Lin FL, Hsiao LT, Liu YC, Wang HY, Ko PS, Lin TA, Chen WC, Chen PM, Liu JH, Gau JP, Liu CJ*. Risk Factors and Outcomes of Stem Cell Mobilization Failure in Multiple Myeloma Patients. *Transfus Med Hemother* 2023;50(1):39-50. (IF:4.04)
 6. ^{2,5}Huang TC, Lo LW*, Chou YH, Lin WL, Chang SL, Lin YJ, Liu SH, Cheng WH, Liu PY, Chen SA. Renal denervation reverses ventricular structural and functional remodeling in failing rabbit hearts. *Sci Rep* 2023;13(1):8664. (IF:4.997)
 7. ^{2,5}Huang WC, Hsieh SC, Wu YW, Hsieh TY, Wu YJ, Li KJ, Charng MJ, Chen WS, Sung SH, Tsao YP, Ho WJ, Lai CC, Cheng CC, Tsai HC, Hsu CH, Lu CH, Chiu YW, Shen CY, Wu CH, Liu FC, Lin YH, Yeh FC, Liu WS, Lee HT, Wu SH, Chang CC, Chu CY, Hou CJY*, Tsai CY. 2023 Taiwan Society of Cardiology (TSOC) and Taiwan College of Rheumatology (TCR) Joint Consensus on Connective Tissue Disease- Associated Pulmonary Arterial Hypertension. *Acta Cardiol Sin* 2023;39(2):213-241. (IF:1.8)
 8. ^{2,5}Kao WY, Tan ECH*, Lee HL, Huang YH, Huo TI, Chang CC, Chiou JF, Hou MC, Wu JC, Su CW*. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy. *Aliment Pharmacol Ther* 2023;57:1299-1312. (IF:7.6)
 9. ^{2,5}Kuo MJ, Lin CY, Lin YJ*, Chang SL, Lo LW, Hu YF, Chung FP, Tuan TC, Chao TF, Liao JN, Chang TY, Kuo L, Wu CI, Liu CM, Liu SH, Chen SA. Insight of electrocardiographic and electrophysiological parameters on the left ventricular function in patients with ventricular arrhythmia from left ventricular summit. *J Cardiovasc Electrophysiol* 2023;34(5):1230-1240. (IF:2.942)
 10. ^{2,5}Kuo MJ, Ton ANK, Lo LW*, Lin YJ, Chang SL, Hu YF, Chung FP, Tuan TC, Chao TF, Liao JN, Chang TY, Lin CY, Kuo L, Wu CI, Liu CM, Cheng WH, Liu SH, Chhay C, Kao PH, Chen WT, Hsu CY, Chen SA*. Abnormal Conduction Zone Detected by Isochronal Late Activation Mapping Accurately Identifies the Potential Atrial Substrate and Predicts the Atrial Fibrillation Ablation Outcome After Pulmonary Vein Isolation. *Circ-Arrhythmia Electrophysiol* 2023;16(2):76-85. (IF:7.718)
 11. ²Li CJ, Chang TE, Hou MC, Huang YH, Lee PC, Chang NW, Chen YJ, Lee FY. Lockdown period during SARS COVID-19 endemic outbreak in Taiwan did not cause an increase of the complications nor mortality of patients received endoscopic retrograde cholangiopancreatography: A single-center retrospective study. *J Chin Med Assoc* 2023;86(2):147-154. (IF:3.0)
 12. ^{2,5}Liang YJ, Chiou YW, Chiu APT, Shiao MS, Teng W, Lin CW, Cheng ML, Huang YH, Liang KH, Su CW, Lai CY, Chen CL, Wu JC*. Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR-122. *J Med Virol* 2023;95(12):- . (IF:12.7)
 13. ²Liu SH, Chao TF*, Chan YH, Liao N, Chen SA. Clinical outcomes of patients with incident atrial fibrillation diagnosed by cardiologists compared to non-cardiologists. *Eur J Intern Med* 2023;112:140-142. (IF:8)
 14. ²Liu SH, Chao TF*, Chan YH*, Liao JN, Chen TJ, Lip GYH, Chen SA. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral

- anticoagulants or stable under warfarin: a nationwide cohort study. *Europace* 2023;25:euad120. (IF:6.1)
15. ²Liu SH, Chhay C, Hu YF*, Lin YJ, Chang SL, Lo LW, Chung FP, Tuan TC, Chao TF, Liao JN, Lin CY, Chang TY, Kuo L, Liu CM, Ton ANK, Yugo D, Chen SA. ABO Blood Groups as a Disease Marker to Predict Atrial Fibrillation Recurrence after Catheter Ablation. *J Pers Med* 2023;13(2):355. (IF:3.4)
 16. ^{2,5}Pun CK, Chang CC, Chuang CL, Huang HC*, Hsu SJ*, Huang YH, Hou MC, Lee FY. Dual angiotensin receptor and neprilysin inhibitor reduced portal pressure through peripheral vasodilatation and decreasing systemic arterial pressure in cirrhotic rats. *J Chin Med Assoc* 2023;86(9):786-794. (IF:3)
 17. ^{2,5}Tsai CY*, Li KJ, Shen CY, Lu CH, Lee HT, Wu TH, Ng YY, Tsao YP, Hsieh SC, Yu CL*. Decipher the Immunopathological Mechanisms and Set Up Potential Therapeutic Strategies for Patients with Lupus Nephritis. *Int J Mol Sci* 2023;24(12):10066. (IF:5.6)
 18. ^{2,5}Tsai SY, Lo LW*, Cheng WH, Liu SH, Lin EJ, Chang SL, Hu YF, Chung FP, Liao ON, Tuan TC, Chao ZF, Lin CY, Chang TY, Liu CM, Chheng C, Hermanto DY, An TN, Elimam AMM, Huang TC, Lee PS, Lee CH, Chen SA*. 10-Year Outcomes of Patients With Non-Paroxysmal Atrial Fibrillation Undergoing Catheter Ablation. *Circ J* 2023;87(1):84-91. (IF:3.35)
 19. ²Tsao YP, Tseng FY, Chao CW, Chen MH, Yeh YC, Abdulkareem BO, Chen SY, Chuang WT, Chang PC, Chen IC, Wang PH, Wu CS, Tsai CY, Chen ST*. NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression. *J Clin Invest* 2023;133(3):e157272. (IF:15.9)
 20. ²Tseng CH, Tseng CL, Chen HS, Chen PL, Huang CJ*. Clinical characteristics of neutropenic patients under antithyroid drug: Twelve-year experience in a medical center. *J Chin Med Assoc* 2023;86(9):826-834. (IF:3)
 21. ^{2,5}Wu CH, Lai CL, Teng CLJ, Fang WL, Huang KH, Li AFY, Yu HY, Chiang NJ, Chao Y, Hung YP*, Chen MH*. Immunoprofile of adenocarcinoma in gastric cancer. *J Chin Med Assoc* 2023;86(6):542-548. (IF:3.396)
 22. ^{2,5}Yen YN, Garrido-Cumbrera M, Sun YS, Chen CH, Lai CC, Tsai HC, Chen WS, Liao HT, Tsao YP, Tsai CY*, Chou CT. The Taiwanese Map of Axial Spondyloarthritis: Living with the Condition. *Med Lith* 2023;59(11):1962. (IF:2.6)